Prevalence of trachoma and risk factors for disease in Benue State, Nigeria by Tagoh, Selassie
 
i | P a g e  
 
 
THESIS TITLE: 
PREVALENCE OF TRACHOMA AND RISK FACTORS FOR DISEASE IN BENUE STATE, 
NIGERIA. 
By 
SELASSIE TAGOH (TGHSEL001) 
Submitted in partial fulfillment of the requirements for the degree 
Master of Public Health (Community Eye Health Specialization) 
in the 
School of Public Health and Family Medicine 
Faculty of Health Sciences 
University of Cape Town 
Cape Town 
South Africa 
Supervisors: Professor Caleb Mpyet 
Submitted: November, 2017 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
 
ii | P a g e  
 
COPYRIGHT 
The copyright of this Thesis vests in the author. No quotation from it or information derived 
from it is to be published without  a full acknowledgment of the source. The thesis is to be 
used for private study or non-comercial research purposes only. 
Published by the University of Cape Town(UCT) in terms of the non-exclusive liscence 
granted to UCT by the author. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii | P a g e  
 
PART 0 (PREAMBLE) 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
iv | P a g e  
 
DECLARATION 
MPH (COMMUNITY EYE HEALTH TRACK) 
I Selassie Tagoh Student Number TGHSEL001 declare that the work that I have submitted for 
the award of this degree is my original work and has not been presented before for the award of a 
Masters’ Degree in Public Health in this University or elsewhere. Where the work of others has 
been used (whether quoted verbatim, paraphrased or referred to) it has been appropriately 
acknowledged and attributed to those authors. 
Signature: S T 
Date:  08/11/2017 
 
 
 
 
 
 
 
 
 
 
v | P a g e
DEDICATION 
I dedicate this work to my mum, dad, brothers, sisters and loved ones. 
 
vi | P a g e  
 
THESIS ABSTRACT 
Background: Trachoma is a common contagious bacterial eye infection caused by Chlamydia 
trachomatis serovariants A, B, Ba or C. It is the leading infectious cause of blindness worldwide 
and is responsible for about 3% of global blindness. World Health Organization (WHO) reports 
suggest that of the 2.2 million people who have been rendered visually impaired worldwide by 
trachoma, 1.2 million are irreversibly blind while an additional 7.3 million people are suffering 
from trachomatous trichiasis (TT) and are at risk of developing blindness. According to WHO 
2007 reports, globally about 84 million people suffer from active trachoma while an estimated 299 
million people still live in trachoma endemic districts. In order to eliminate trachoma as a public 
health problem, The Global Trachoma Mapping Project (GTMP) was initiated on 23 July 2012 as 
a first step in generating population-level prevalence estimates of the disease so as to determine 
the need for intervention. Between 2013 and 2015, the GTMP mapped suspected endemic districts 
including Benue state of Nigeria. This current study took advantage of this data to generate 
prevalence information on Trachomatous inflammation Follicular (TF) and Trichiasis for Benue 
state and to describe the some of the household risk factors associated with the disease. The thesis 
is structured in three parts 0(Preamble), A (Protocol), B (Literature Review), C (Article) and D 
(Appendix).  
Methods: A two-stage cluster random sampling technique was utilized in a population based 
prevalence survey to generate estimates for TF and Trichiasis. 
Results: Overall unadjusted prevalence of TF among persons 1-9 years was 2.00% (95% CI: 1.20 
– 2.98) and that of trichiasis among persons ≥15 years was 0.11% (95% CI 0.06 – 0.12). Trichiasis 
was more prevalent among adult women 0.05% (95% CI: 0.03 – 0.07) compared to males 0.03 % 
(95% CI: 0.02 – 0.05), (p=0.13). LGA-level prevalence of TF and Trichiasis among persons 1-9 
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years and persons ≥15 years ranged from 0.30% (95% CI: 0.1–0.5) to 5.30% (95% CI: 3.30–7.70) 
and 0.00% to 0.35% (95% CI: 0.12–0.50) respectively. Two LGAs had trichiasis prevalence above 
0.2%. TF prevalence was between 5% and 9.9% in 2 LGAs. The common risk factors identified 
included age, sex, inaccessibility to water and latrine facility. Adults ≥15 years were 8.94(95%CI: 
2.79 – 29.64) times more likely to have trichiasis compared to persons between 1-9 years of age. 
Conclusion: Trachoma was found to be a public health problem in 3 LGAs of Benue state. One 
round of mass antibiotic distribution will be required in 2 LGAs. With an estimated trichiasis 
backlog of 1,064, about 173 individuals with trichiasis needed to be managed to reduce the 
prevalence to less than the elimination threshold.  
Key words: Prevalence, Trachoma, Nigeria, Benue State, trichiasis. 
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1.0 Background 
Trachoma is one of the over 13 Neglected Tropical Diseases (NTDs) responsible for different 
forms of disability in many low and middle income countries worldwide (Neglected Tropical 
Diseases...WHO, 2009). It is a major cause of visual impairment and blindness globally and 
estimated to be endemic in 33 countries in Africa. It also has significant presence in other under- 
developed continents including Asia, Latin America, Middle east and the Western Pacific 
(Alemayehu et al., 2015; Polack et al., 2005).The continuous presence of trachoma in these 
regions, is in spite of the fact that its natural history, including treatment, control and elimination 
mechanism have been widely studied and recommended by the WHO (WHO, 2013). Recent 
reports have shown that trachoma is the leading infectious cause of blindness worldwide (Asres, 
Endeshaw & Yeshambaw, 2016; WHO, 2013) and is responsible for 3% of global blindness 
(Pascolini & Mariotti, 2011). According to the same report, out of the over 2.2 million people 
rendered visually impaired worldwide by trachoma, 1.2 million are irreversibly blind. 
Additionally, 2007 reports by the WHO showed that globally about 84 million people suffer from 
active trachoma (Trachomatous inflammation, Follicular [TF] and/or Intense [TI]) (Burton & 
Mabey, 2009; Ketema et al., 2012) while an estimated 299 million people still live in trachoma 
endemic districts (WHO, 2014) including 7.3 million people suffering from TT and at risk of 
developing blindness (WHO, 2012) from recurrent trachoma infections. 
Trachoma infection is characterized initially by an inflammation of the inner lining of the eye lids 
(palpebral conjunctiva) usually in childhood. Recurrent episodes of infection eventually results in 
conjunctival scars leading to entropion and trachomatous trichiasis (Mariotti, Pascolini & Rose-
Nussbaumer, 2009). Persistent rubbing of eyelashes on the cornea results in complications causing 
severe pain, corneal opacity and subsequent vision loss in older children and adults (Thylefors et 
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al., 1987). Transmission of trachoma has been known to be facilitated through direct contact from 
dirty fingers, fomites such as cloths, towels, bed sheets as well as the eye-seeking fly Musca 
sorbens which predominantly prefers human faeces as a best larval medium for breeding purposes 
(Emerson et al., 2001; Taylor, 2008) and are responsible for the increased prevalence of the disease 
especially in Africa.  
The prevalence and risk factors for trachoma in Africa have been reported on by several population 
based studies including a recent study by Asres et al (Asres, Endeshaw &Yeshambaw, 2016). In 
this study, it was observed that communities endemic of  trachoma were usually located in dry and 
dusty regions with insufficient or distant water sources, for which reason they practice poor face 
washing and general personal hygiene habits (Asres, Endeshaw &Yeshambaw, 2016). 
Additionally, findings from this survey showed that other socio-demographic factors like age, sex, 
educational level of child and parents, presence of trachoma in other family members, poor 
household economy and poor personal and environmental hygiene were predictors of trachoma in 
children 1-9 years old. In 2005, a study by Polack et al also reported on the difference in prevalence 
of trachoma in the different climatic zones. Dry climatic zones were found to have the highest 
prevalence of 24.2 % (Polack et al., 2005). Factors like poverty, poor sanitation, high fly density, 
absence of latrine and low socio-economic status have also been reported to be strongly associated 
with the regions where the condition is hyperendemic (Asres, Endeshaw &Yeshambaw, 2016; 
Ketema et al., 2012). 
Trachoma has been eliminated as a public health problem in many developed countries even 
though high prevalence of the disease has been recorded in some parts of Northern, Southern and 
Western Australia (Lansingh et al., 2001; Tellis, Keeffe & Taylor, 2006). Successful elimination 
in most developed countries was largely due to socio-economic development, improved access to 
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water and improved sanitation in the areas of personal and environmental hygiene (WHO, 2013). 
The disease however persists in some vulnerable communities especially in Africa as most of the 
countries with excess burden of the disease are located in this region (Polack et al., 2005).                                                                                
In Africa and globally, Ethiopia carries the largest burden of the disease (WHO, 2014). The 
national survey of blindness and low vision (2007) in Ethiopia reported that trachoma was the 
second largest cause of visual disability. It was responsible for 7.7% of low vision and 11.5% of 
blindness. The overall prevalence in this survey was greater in rural populations and among 
women. It was concluded that trachoma was hyperendemic, with prevalence estimates as high as 
40.1% found among children aged 1-9 years (Berhane et al., 2007). Other surveys have however 
reported not so high prevalence estimates of TF and TT among children and adults respectively in 
Ethiopia (Yalew et al., 2006). Nevertheless, the reported prevalence estimates were still higher 
than the WHO elimination threshold of <5% for TF and < 0.1% for TT. 
Studies in Malawi by Kalua et al., reported a 17.1% {95% CI: 14.9 – 19.4} prevalence of (TI) and 
(TF) among children aged 1 - 9 years. Furthermore, it was observed that prevalence of TF tended 
to reach peak between two and four years of age as children this age are more likely to play around 
and live in unhygienic environments. In addition, prevalence of TF was found to be significantly 
higher among girls than in boys {19.4% versus 14.6%; p = 0.034} (Kalua et al., 2014). The 
prevalence of (TT) in women aged 15 years and above was 1.3% {95% CI: 0.7– 2.3}, while the 
prevalence in men was zero. The high prevalence in women compared to men could be explained 
by the increased probability of recurrent infection of women since they are most likely to take care 
of the infected children.  TF was significantly correlated with absence of a “clean face” {P < 0.001} 
and absence of a toilet facility {p< 0.001}, but results differed in terms of presence of solid waste, 
animal pens and distance to water source (Kalua et al., 2014). Similar population based surveys 
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conducted in endemic districts in Senegal (Saal et al., 2003), Gambia (Dolin et al., 1998) and 
Nigeria (Jip et al., 2008; Mansur, Muhammad & Liman, 2007; Mpyet, Ogoshi & Goyol, 2008)  
also yielded similarly  high levels of prevalence values that far exceeded the WHO stipulated  
threshold  (TF≥5% and TT >0.1% ) for intervention. Even though these studies may have differed 
slightly in terms of sample size, methodology and outcome measures examined, they however 
provide an idea of the global picture of the burden of trachoma on the continent, to which Nigeria 
contributes significantly.                                                                   
Nigeria is the most populous nation in Africa, with a population of about 186.1 million (US Census 
Bureau, 2016). Due to its size and land area (923,768 sq km), a large portion of its land mass falls 
within the dry and arid Sahel region of West Africa with climatic conditions which reportedly 
favour trachoma endemicity (Rabiu & Abiose, 2000). The National survey of causes of blindness 
and visual impairment in Nigeria (2005-2007) reported an overall blindness prevalence of 5.5% 
among individuals ≥50 years and 1.5% of severe visual impairment (National Blindness Survey..., 
2008). In the same report, Trachoma was mentioned to be responsible for 4.2% of blindness. 
Blindness from trachoma has been predominantly reported in the northern part of the country 
(Rabiu &Abiose, 2000).   
WHO has a recommended elimination strategy for trachoma. This includes the four pronged 
combination of interventions referred to as “SAFE” strategy (S: Surgery of the eyelids for those 
with TT and are at immediate risk of blindness, A: Antibiotics to treat individual cases and to 
reduce infection in a community, F: Facial cleanliness and hygiene promotion to reduce 
transmission and E: Environmental changes such as provision of water and household sanitation 
(Bailey & Lietman, 2001). However, the only way to know which aspect of the “SAFE” strategy 
to be implemented is by assessing all persons in suspected endemic communities who are 1 year 
 
8 | P a g e  
 
old and above for the presence of the five common signs that characterize the clinical features of 
trachoma under the WHO simplified grading system; Trachomatous inflammation Follicular (TF), 
Trachomatous inflammation Intense (TI), Trachomatous Scarring (TS), Trachomatous Trichiasis 
(TT) and Corneal Opacity (CO) (Thylefors et al., 1987).  
In order to properly assess the distribution and magnitude of trachoma globally so that elimination 
strategies can be planned and targeted at the countries and communities most at risk, the Global 
Trachoma Mapping Project (GTMP) was undertaken between January 2012 and December 2015 
to generate prevalence data on the burden of trachoma in communities in 34 countries globally 
including Benue state in Nigeria.  
Benue is one of the states in the North-Central part of Nigeria. It has 23 LGAs with a population 
of about 4.2 million (Population and Housing Census, 2006). Due to its location in the dry, arid 
climatic zones of the country with  maximum temperatures ranging between 36.0°C-38.0°C during 
the hot season (Nigeria Climate Review, 2012), coupled with reports of  trachoma endemicity in 
neighbouring Nasarawa and Plateau states (King et al., 2010), it was suspected that trachoma may 
be endemic in some districts of Benue state. Even though there have been reports of river blindness 
(Onchocerciasis) in most communities in this state (Gemade & Utsalo, 1990; Manyi, Obi & 
Iortyom, 2014), little or no published information exists on prevalence of trachoma. This study 
therefore seeks to ascertain the prevalence and risk factors for TF and trichiasis among children 1-
9 years old and adults ≥ 15 years old respectively in Benue state so as to decide whether it is 
necessary to establish an elimination programme in communities within this state.  
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2.0. Purpose of the Study 
2.1 Aim 
The aim of this study is to determine the prevalence and risk factors for trachoma among children 
between 1 -9 years old and adults ≥15 years old in Benue state of Nigeria. 
2.2 Objectives 
1. To determine the prevalence of Trachomatous inflammation Follicular (TF) and 
Trichiasis among children 1-9 years and adults ≥15 years old respectively in Benue 
State of Nigeria and to decide which Local Government Areas (LGAs) are endemic 
of the disease and warrant a trachoma control programme. 
2. To describe the demographic distribution of TF and Trichiasis among children 1-
9 years old and adults ≥15 years old respectively in Benue state, Nigeria. 
3. To describe the individual and environmental risk factors associated with 
Trachoma in Benue state, Nigeria. 
4. To determine the association between the prevalence of Trachoma (TF, Trichiasis) 
and gender in the population studied. 
5. To determine the association between the prevalence of Trachoma (TF, Trichiasis) 
and age in the population studied. 
6. To estimate the number of antibiotics treatments and trichiasis surgeries to be 
performed to eliminate trachoma as a public health problem in Benue state. 
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3.0. Methodology 
3.1 Definition of terms 
 Table. 1 Definition of terms used in the protocol 
Term Definition 
Active trachoma Trachomatous inflammation, follicular 
or Trachomatous inflammation intense 
Binocular Loup Potable optical magnifying instrument for 
observing the external structures of the eye. 
Confounding factors A variable that is correlated (directly or 
inversely) to both the dependent variable 
and independent variable. 
Demographic variable “Personal statistics that include such 
information as income level, gender, 
educational level, location, ethnicity, race, 
and family size” 
Entropion Inward folding of the eyelids 
Epilation Removal of in-turned lashes 
Tarsal conjunctivae The epithelial tissue that lines the inside of 
the eyelids  
Trachomatous Trichiasis At least one eyelash rubbing the eyeball or 
evidence of recent removal of in-turned 
eyelashes. 
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Trachoma Grader An eye care professional trained and 
certified to assess patients for signs of 
trachoma. 
Trachomatous Inflammation Follicular Presence of at least five or more follicles in 
the upper tarsal conjunctiva each at 
least 0.5mm in size. 
 
3.2 Study Design  
The study will be a population-based analytical cross-sectional study using pre-existing data 
obtained from a GTMP survey conducted in Benue state between April and September 2014. The 
data from this project were obtained through a multi-stage cluster random sampling technique as 
recommended by WHO. The methods and techniques described in this study will therefore be 
significantly consistent with the methodology as described elsewhere (Solomon et al., 2015). This 
study will essentially be an analysis of the data from a combination of examination of clinical signs 
for trachoma and questionnaire-based assessment of potential household-level risk factors for 
trachoma in the study population. 
3.3 Sample size 
In LGAs, 25 villages will be selected using a multi-stage approach with probability of selection of 
the village being proportional to the village population size. In each village 25 households will be 
selected according to the single population proportion for precision formula. In order to estimate 
expected TF prevalence of 10% and to report a 95% Confidence Interval (CI) with absolute 
precision of 3%, a minimum of 384 children aged 1–9 years selected by simple random sampling 
would be required. This number will be adjusted by a design effect of 2.65 and  further inflated by 
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a factor of 1.2 to account for non-response rate to arrive at a final minimum. This sampling strategy 
was designed to promote recruitment of a sample of at least 1019 children aged 1–9 years. The 
low prevalence of TT (nearly always <2% in adults except in the most hyperendemic areas) means 
that accurately estimating its prevalence requires prohibitively large samples, and we will accept 
the loss of precision in the estimate of trichiasis prevalence inherent in this approach. It is planned 
to examine all adults found in each selected household. 
3.4 Characteristics of Study population 
The study population will be a cross-section of the population of Benue state, Nigeria. The state is 
located in the North– Central zone of Nigeria with a population of about 4.2 million and a land 
area of 34,059 square km. It is predominantly an agricultural rich region transcended by numerous 
rivers and is sometimes referred to as the “food basket” of Nigeria because of the abundant 
production of crops like yam, potatoes, cassava, soya bean, guinea corn and flax among others. 
Data from the Nigeria population census in 2006 shows that 50% of the population are females 
while 34% of the population is between 0-9 years old. The population includes a diverse number 
of ethnic groups distributed in 23 different districts (LGAs). 
3.4.1 Inclusion Criteria 
All residents of Benue state 1 year and older in the selected clusters will be included in the study. 
Data obtained from all participants included in the survey will be analysed. 
3.4.2 Exclusion Criteria 
Children who did not fall within the study age group (<1year old) and population will be excluded. 
3.4.3 Sample recruitment and enrolment 
The data from this project will be obtained through a Multi-stage cluster random sampling 
technique as recommended by WHO. Surveys will be conducted in all 23 LGAs of Benue State. 
In each LGA a 2-stage cluster random sample technique will be used to randomly select the study 
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subjects. In stage 1, 25 villages (clusters) will be selected from a list of all villages in the LGA 
using probability proportional to the village population size technique. In stage 2, twenty-five 
households will be randomly selected from each selected village to be included in the study.  
With the help of a local guide, the centres of the villages will be located. A pen will be spun on 
the ground at this location and the direction which the pen points will be observed. This direction 
will then be followed by a survey team and all eligible households in this direction will be selected 
and their residents examined (Random walk method) until the required number of households have 
been assessed. Survey teams will examine all residents for clinical signs of trachoma and also 
question household heads about water and sanitation facilities.  Team members will also directly 
observe sanitation facilities available in the households selected.  
3.5. Variables 
Table 2. Variables that will be used for data analysis 
Name Type of variable Unit Possible value 
Age Numerical years 1-9 for children, ≥15+ 
for adults 
Enumeration Unit Categorical - Coded:380-402 
Sex Categorical - Male. Female 
Trachomatous 
Follicular (TF) 
Categorical - Present, Absent 
Trachomatous 
Trichiasis 
Categorical - Sign Present, sign 
Absent, Not able to 
grade 
 
Drinking water 
source, Face 
washing water 
source 
 
Categorical 
-  
Improved (Piped 
water into dwelling, 
Piped water into yard, 
Tub well, Protected 
spring, Borehole, 
Protected dug well, 
Rainwater collection 
Unimproved 
(Unprotected dug 
well, 
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Unprotected spring, 
Water vendor,  
Surface water,  
Other) 
Distance from drink 
water source, 
Distance from face 
washing water 
source 
Categorical -  Less than 30 minutes, 
Between 30 minutes 1 
hour,  
Latrine Facility Categorical - Present (Shared 
latrine,  
Private latrine),  
Absent (No structure 
outside/ near house,  
No structure in the 
bush or field) 
 
Type of latrine Categorical - Improved (Flush/ 
pour 
Flush/pour flush to 
septic tank 
Flush/pour flush to pit 
Latrine Ventilated 
improved pit latrine 
(VIP), Composting 
toilet, Pit latrine with 
slab) 
 
Unimproved 
(Flush/pour flush to 
open drains 
Flush/pour flush to 
unknown place 
Bucket 
Hanging 
toilet/hanging latrine 
No facilities or bush 
or field, 
Others) 
 
Hand washing 
facility within latrine 
facility. 
 
Categorical 
-  
Yes, No 
 
Water available at 
hand washing 
facility 
Categorical - Yes, No 
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Soap/ash available at 
hand washing 
facility 
Categorical - Yes, No 
    
 
3.6. Procedure and data collection 
In the randomly selected households, all residents over the age of 1 will be invited to participate. 
After exchanging pleasantries with the head of household, the conduct of the survey will then be 
thoroughly explained and his/her consent will be  sought, after he or she has demonstrated adequate 
understanding of the survey protocols and is satisfied with measures to ensure confidentiality and 
privacy.  
If household head consents to participate, global positioning system (GPS) coordinates will then 
be collected from outside the front door of the house or compound. Information on potential 
household-level environmental risk factors for trachoma will then be obtained through household 
heads responses to questions on a pre-validated WaSH questionnaire.  The questionnaire that will 
be used in this survey will be that of the WHO/UNICEF (United Nations International Children’s 
Emergency Fund) Joint Monitoring Programme (WHO/UNICEF, 2006) and will be administered 
by the survey team. Visual inspection of household latrine and hand washing facilities will also be 
carried out.  
Participants who will give consent to participate in the study will then be examined by trained and 
certified GTMP graders for signs of TF and trichiasis according to the WHO simplified grading 
system (Thylefors et al., 1987). This exercise will be conducted using a 2.5x magnifying binocular 
loupe in bright sunlight or with torchlight for adequate illumination. The process is estimated to 
last maximum of about 15 minutes so as to avoid participant fatigue. Households with absent 
residents on first visit will be re-visited by the team at the end of the day to get them examined. 
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Adequate precautions will be taken to prevent microbial cross-infection of participants of the study 
by using alcohol based hand sanitizers in-between examination of study subjects.  
All the data will be electronically captured using a purpose-built Open Data Kit-based Android 
smart phone application called LINKS developed by the Task Force for Global Health, Atlanta, 
GA, USA (Pavluck et al., 2014).The data will be kept on the Smartphone’s micro-secured digital 
card, which will allow continuous storage of the data until a data-enabled mobile network or WiFi 
signal is available for the data to be transmitted.  
3.7. Data Safety and Monitoring 
The GTMP data will be geographically referenced using GPS system coordinates. They will then 
be transmitted to a high security server for cleaning by designated data managers and to undergo 
the various levels of approval by persons at the Ministry of Health who will endorse the adequacy 
of data collection and appropriateness of the data cleaning process. To ensure inter-and intra-rater 
reliability, survey team members will be well trained on data collection protocols and procedures. 
3.8. Data Analysis Plan 
The main aim of this study is to determine the prevalence of trachoma marked by the main signs 
of the disease in children 1-9 years old (TF) and in adults 15 years and above (Trichiasis). In this 
research, the de-identified cleaned GTMP electronic data will be imported into Stata (Version 
14.0) for analysis.  
Exploratory statistical techniques will be conducted to ascertain the appropriateness of intended 
statistical tests. For objectives 1 and 2, the data will be summarized using appropriate descriptive 
statistics such as frequencies and percentages for categorical variables while numerical variables 
will be summarized using means and medians. Additionally the risk factors for trachoma and 
percentage prevalence of TF in 1-9 year olds and trichiasis in adults ≥ 15 years including the 
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demographic distribution of these parameters will be explored using simple descriptive statistical 
tests. This will include calculation of the proportion of subjects in the overall sample and within 
each LGA with the relevant signs of trachoma for the two age categories.  
With respect to objective 3, the independent individual and household risk factors for trachoma 
will be determined by univariate and multivariate logistic regression models, while adjusting for 
relevant potential confounding factors like, age, gender, household source of drinking water in the 
dry season, household source of face washing water in the dry season, distance of household from 
water source, presence of latrine in household, type of latrine, presence of hand washing facility 
close to latrine, presence of  water and soap close to latrine for hand washing. Prevalence of 
trachoma (TF/trichiasis) will be used as dependent variable. Crude and adjusted Odds ratios, p-
values and 95% Confidence Intervals will be generated and reported for the precision of estimates.  
For objectives 4 and 5, correlation coefficients will be calculated to determine how prevalence of 
trachoma relates to gender and age. Objective 6 will be achieved based on the prevalence estimates 
of trachoma and the projected population of the respective LGAs.  
TF prevalences of >10% is considered a public health problem, however who recommends that 
TF prevalences of between ≥5%- 9.9 % and ≥10-20.9%  will require one round and three rounds 
of mass distribution of antibiotics (azithromycin) respectively in addition to environmental and 
facial cleanliness campaigns. TT prevalence of ≥0.2% in persons ≥15 years also calls for 
implementation of the “S” component of the “SAFE” strategy (WHO, 2003). 
 
18 | P a g e  
 
4.0. Description of Risks and Benefits 
4.1. Potential Risks 
Examination for trichiasis is harmless and if any at all, participants will experience only a transient 
discomfort (minimal risk) during eversion of the tarsal conjunctivae to allow examination for TF 
and TI. Qualified well trained trachoma graders will be engaged in data collection to ensure 
minimal or no harm to participants. No risks of any kind are anticipated from this current study as 
only secondary data will be used for analysis.  
4.2 Potential Benefits 
The community however stands to benefit from this study in that results will inform government 
and relevant stakeholders of the need or otherwise to establish trachoma elimination programme 
in endemic communities in Benue state. Individuals who were found to have signs of TF will also 
benefit from drugs (1% tetracycline ointment) for treatment of the condition and those suspected 
of trichiasis will be counselled and referred to nearby hospitals for evaluation and management. 
5.0. Ethical Considerations 
5.1 Informed Consent Process 
The protocols of the study and the examination modalities will be thoroughly explained to each 
adult before the GTMP data will be collected. They will be allowed to consult with other household 
members before giving consent. It is anticipated that most of the participants will not be able to 
read nor write, hence the explanation of the study protocols will be done in a local language by 
selected survey team members who will be recruited and trained in the sampling protocol, 
interview process, and the method for completing survey forms.  
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5.2 Capacity to consent 
Verbal consent for enrolment and participation will be obtained from each household head, parents 
or legal guardians (for minors) before examinations will be conducted.  Adult participants will be 
made to give verbal consent for their own participation. Consent will then be documented on 
individual consent forms and also stored on the LINKS application purposely designed for this 
type of surveys. Permission will be sought from relevant stakeholders before using the baseline 
data for any secondary analysis. . 
5.3 Comprehension of information 
It will be ensured that participants are given adequate information about the study examination 
and modalities. Participants will be allowed to give consent only after demonstrating adequate 
understanding of the information they will be given. Participants will not be directly involved in 
any way during analysis of the data obtained during the survey. 
5.4 Privacy and Confidentiality 
The data for the study will be in the custody of representatives of the Nigeria trachoma control 
programme and persons granted permission by them to use it for publication purposes. Permission 
will be sought from these representatives before any secondary analysis of the data is done. These 
representatives therefore reserve the explicit right to an informed release of the data for the 
purposes of future research. The data will be in an electronic form only and could be assessed only 
by the researcher. The data will be kept on a personal computer with a password only known to 
the researcher. The data itself will be kept in a password protected folder that can only be assessed 
by the researcher. 
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5.5 Emergency Care and Insurance for Research-related Injury 
No research related injury is anticipated in this study. This is because only secondary data will be 
used in this study for analysis. Since participants are not going to be directly involved, there will 
be no need for any emergency care or insurance cover for any related injury or harm. 
5.6. Institutional Review Board Approval 
Copies of the research protocol will be sent to the University of Cape Town Research Ethics 
Committee and Departmental Research Committee for approval. Prior to collection of the GTMP 
data, the project will be approved by the Ethics Committee of the London School of Hygiene and 
Tropical Medicine and the National Health Research Ethics Committee of Nigeria while the 
government of Benue state will be asked permission for the conduct and appropriate report of the 
study. Data collection methods will also conform to the guidelines of the Declaration of Helsinki. 
6.0. Justification for the study 
Trachoma is the most common infectious cause of blindness worldwide hence the WHO has put 
in place programmes aimed at eliminating trachoma as a public health problem by the year 
2020.The “SAFE” strategy is the recommended approach proposed by WHO to deal with the 
problem of trachoma in endemic communities. However to achieve the aims of the GET 2020 
project, there is a need for a complete understanding of the distribution and intensity of the 
endemicity of blinding trachoma globally. Population based surveys are therefore necessary 
critical steps in the achievement of this aim, as they provide baseline information on the district-
level prevalence of the disease. 
Reports have shown that the global burden of trachoma has not been fully assessed. According to 
2012  reports in the GTMP methodology paper, population based surveys have been conducted 
over the years  to map  trachoma in about 1115 districts worldwide with data thought to be required 
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from about 1238 more districts so as to complete the global picture. This study is therefore being 
conducted to generate baseline prevalence data on the clinical signs of TF among children 1-9 
years old and trichiasis among adults ≥15 years of age in Benue state of Nigeria.  This is vital 
information that can be used for advocacy purposes aimed at attracting local and international 
support to eliminate trachoma as a public health concern in Nigeria.  
In addition, the results of this research will supplement already existing knowledge about the 
global burden of trachoma and further help to complete the global trachoma map.  It will also 
enhance the understanding of the true nature of the task involved in eliminating trachoma as a 
public health problem. Furthermore, the baseline data that will be generated from this study can 
be used by programme managers as a guide to facilitate the planning of trachoma elimination 
programmes for endemic communities. 
This research is necessary because it will also enable trachoma programme managers estimate the 
number of antibiotics treatments as well as the number of trichiasis surgeries needed for endemic 
communities in Benue state in order to eliminate trachoma as a public health problem. This 
information will be valuable in the control programme planning process in terms of making request 
for the consumables required for the elimination programme. 
If all these purposes are achieved, this study will ultimately be contributing to efforts to reduce 
avoidable causes of blindness, as many people will be prevented from going blind unnecessarily 
from trachoma. The study will essentially be contributing significantly to WHO efforts directed at 
achieving the aims of VISION 2020 and the GET 2020 initiative. 
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7.0. Budget 
No budget is required for this study because there is no direct cost to the researcher except for time 
and commitment. The survey field work has already been conducted and the data is available for 
research purposes upon request and approval from relevant institutions. 
8.0. Available Resources 
Supervision support will be provided by supervisors from University of Jos, Nigeria and 
University of Cape Town, South Africa. UCT will provide access to bibliographic references and 
software for the analysis as this final dissertation forms part of the MPH course. No additional 
resources will be needed as the student researcher’s personal computer will be used to do the 
analysis. 
 
 
 
 
 
 
9.0. Timeline 
The study will be conducted between October 2016 and October 2017. Table 3 provides a timeline 
of events from the start of protocol development to final submission to UCT post graduate office 
and submission to journal for publication.  
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Table 3: Research timeline 
Task  Description Month October, 
2016 
November, 
2016 
December, 
2016 
January, 
2017 
February, 
2017 
March-
November, 
 2017 
  Week 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4  
1 Protocol Completion                      
1.1 Supervisors’ Approval                      
1.2 Final draft for Departmental 
review 
                     
1.3 Protocol Defence                      
1.4 Feedback for revision                      
1.5 Final draft completed                      
1.6 Submission to ethics                      
1.7 Ethics Approval                      
2 Data Analysis                      
2.1 Preliminary Analysis                      
2.2 Data analysis                      
3.0 Write up                      
3.1 Draft manuscript                      
3.2 Feedback and review                      
3.3 Draft  dissertation to 
supervisor 
                     
3.4 Feedback and review                      
3.5 Feedback and review                      
3.6 Finalize dissertation                      
4.0 Submissions                      
4.1 Notice of submission to 
UCT 
                     
4.2 UCT submission                      
4.3 Submission to Journal                      
 
10.0. Dissemination of Results 
The results of the study will be disseminated to all relevant stakeholders including the Ministry of 
Health of the Federal Republic of Nigeria. Additionally the results will be published in a peer-
reviewed scientific journal so that it can be available to the wider scientific audience. 
 
24 | P a g e  
 
11.0. References 
1. Alemayehu, M., Koye, N. D., Tariku, A., Yimam, K. 2015. Prevalence of Active 
Trachoma and its Associated Factors among Rural and Urban Children in Dera 
Woreda, North-west Ethiopia: A Comparative Cross-Sectional Study. Bio Medical 
Research International. 1-8. Available: http://dx.doi.org/10.1155/2015/570898   [2016, 
July 13]. 
2. Asres, M., Endeshaw, M. &Yeshambaw, M. 2016. Prevalence and Risk Factors of 
Active Trachoma among Children in Gondar Zuria District North Gondar, Ethiopia. 
Insight Medical Publishing Journals. (1)1:5. Available: http://preventive-
medicine.imedpub.com/ [2016,July 10]. 
3. Bailey, R.  & Lietman, T. 2001. The SAFE strategy for the elimination of trachoma by 
2020: will it work? Bulletin of the World Health Organization. 79: 233–236. Available: 
http://www.who.int/bulletin/archives/79(3)233.pdf [2016, July 19]. 
4. Berhane, Y., Worku, A., Bejiga, A., Adamu, L., Alemayehu, W., Bedri, A., Haile, Z., 
Ayalew, A., et al.2007. Prevalence and causes of Blindness and Low Vision in 
Ethiopia. Ethiopia Journal of Health Development. 21; (3): 204-210. Available: 
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.574.3501&rep=rep1&type
=pdf [2016, July 11].  
5. Burton, M.J & Mabey, D.C.W. 2009. The Global burden of Trachoma: a review. PLoS 
Neglected Tropical Diseases. 3 (10):e460.  
 DOI:  http://dx.doi.org/10.1371/journal.pntd.0000460. 
6. Dolin, P. J., Faal, H., Johnson, G. J., Ajewole, J., Mohamed A.A. & Lee P. L. 1998. 
Trachoma in the Gambia. British Journal of Ophthalmology. 82:930-3. DOI: 
10.1136/bjo.82.8.930. 
 
25 | P a g e  
 
7. Emerson, P. M., Bailey, R. L., Walraven G. E. & Lindsay, S. W. 2001. Human and 
other faeces as breeding media of the Trachoma Vector Musca sorbens. [Abstract]. 
Medical and Veterinary Entomology. 15(3):314–320.  
DOI: 10.1046/j.0269-283x.2001.00318.x.  
8. Gemade, E. I. &Utsalo, S.J. 1990. Onchocerciasis in Benue State of Nigeria. VI: The 
Prevalence and Distribution of the Disease among the Human Population in Sati-Ikyov 
village. Acta Leiden. [Abstract]. 59 (1-2):51-8. 
 Available: www.ncbi.nlm.nih.gov/pubmed/2378227 [2016, July 21]. 
9. Jip, N. F., King, J. D, Diallo, M. O., Miri, E. S., Hamza, A. T., Ngondi, J.& Emerson, 
P. M. 2008. Blinding trachoma in Katsina State, Nigeria: Population-based prevalence 
survey in ten local government areas. [Abstract].Ophthalmic Epidemiology. 15(5): 
294–302.  DOI: 10.1080/09286580802256542. 
10. Kalua, K., Isaac Singini, I., Mukaka, M., Msyamboza, K., Masika, M. & Bailey, R. 
2014.Scaling up of trachoma mapping in Salima District, Central Malawi. 
International Journal of Tropical Diseases & Health. 4(5) 494-508. Available: 
http://dx.doi.org/10.4236/health.2014.61009  [2016, July 21]. 
11. Ketema, K., Tiruneh, M., Woldeyohannes, D., Muluye, D.2012. Prevalence of active 
Trachoma and associated risk factors among children less than ten years in Baso Liben 
district, East Gojjam. Ethiopia. Bio Medical Central, Public Heath.1-7. 
DOI: 10.1186/1471-2458-12-1105. 
12.  King, D., Jip, N., Jugu Y. S., Othman, A., Rodgers, A. F., Dajom, D. Y., Miri, E & 
Emerson P. M. 2010.Mapping Trachoma in Nasarawa and Plateau States, Central 
Nigeria. British Journal of Ophthalmology. 94:14–19. DOI:10.1136/bjo.2009.165282. 
 
26 | P a g e  
 
13. Lansingh, V.C., Weih, L.M., Keeffe, J.E. & Taylor, H.R. 2001. Assessment of 
Trachoma prevalence in a mobile population in Central Australia [Abstract]. 
Ophthalmic Epidemiology. 8(2-3):97-108.  
Available: http://www.ncbi.nlm.nih.gov/pubmed/11471079  [2016, July 10]. 
14. Mansur, R., Muhammad, N. & Liman, I. R. 2007. Prevalence and magnitude of 
Trachoma in a Local Government area of Sokoto State, North Western Nigeria. 
[Abstract]. Niger Journal of Medicine. 16: 348–353.  
Available: http://www.ncbi.nlm.nih.gov/pubmed/18080594  [2016, July 12]. 
15. Mariotti, S. P., Pascolini, D., Rose-Nussbaumer, J. 2009. Trachoma: Global magnitude 
of a preventable cause of blindness. British Journal of Ophthalmology. 2009. 93:563–
568. DOI:10.1136/bjo.2008.148494. 
16. Mpyet, C., Ogoshi, C. & Goyol, M. 2008. Prevalence of Trachoma in Yobe State, 
north-eastern Nigeria. Ophthalmic Epidemiology. 15: 303–307. 
DOI: 10.1080/09286580802237633. 
17. National Population Commission. 2006.  Population and Housing Census of the 
Federal Republic of Nigeria. Priority Tables. Volume 1. Available: 
http://www.population.gov.ng/index.php/publications/138-national-and-state-
population-and-housing-tables-2006-census-priority-tables-vol-1.  [2016, August 13]. 
18. Nigerian Climate Review. 2012. Edited Report. 13-14. Available: 
http://www.nimet.gov.ng/sites/default/files/publications/2012%20NIGERIAN%20CL
IMATE%20REVIEW%20EDIT.docx.  [2016, August 14]. 
 
27 | P a g e  
 
19. Pascolini, D. & Mariotti, S. P. 2011. Global estimates of Visual Impairment: 2010. 
British Journal of Ophthalmology. 96(5):614–618. DOI: 10.1136/bjophthalmol-2011-
300539. 
20. Pavluck, A., Chu, B., Flueckiger, M. R. & Ottesen, E. 2014. Electronic Data Capture 
Tools for Global Health Programs: evolution of LINKS, an Android-, web-based 
system. PLoS Neglected Tropical Diseases. 8(4): e2654.  
DOI: 10.1371/journal.pntd.0002654. 
21. Polack, S., Brooker, S., Kuper, H., Mariotti, S., Mabey, D., Foster, A. 2005. Mapping 
the global distribution of trachoma. Bulletin of the World Health Organization. 83 
(12).Available: http://www.who.int/bulletin/volumes/83/12/913.pdf [2016, July 9]. 
22. Rabiu M, M. & Abiose, A.  2001. Magnitude of trachoma and barriers to uptake of lid 
surgery in a rural community of northern Nigeria. Ophthalmic Epidemiology. (8), 2-3,   
181-790. Available: 
http://www.ph.ucla.edu/epi/rapidsurveys/ophthalmicepid8(2_3)_181_190_2001.pdf 
[2016, July 17]. 
23. Saal, M. B., Schemann, J. F., Saar, B., Faye, M., Momo, G., Mariotti, S. & Negrel, A. 
D. 2003. Trachoma in Senegal: results of a National survey [Abstract]. Med Trop 
(Mars). 63(1):53-9. Available: 
https://www.researchgate.net/publication/10634730_Trachoma_in_Senegal_results_o
f_a_national_survey  [2016, July 11]. 
24. Solomon, A. W., Pavluck, A. L., Courtright, P., Abo, A., Adamu, L., Alemayehu W., 
Alemu, M. & Alexander N.D.E et al. 2015. The Global Trachoma Mapping Project: 
 
28 | P a g e  
 
Methodology of a 34-Country Population-Based Study. Ophthalmic Epidemiology. 
22(3): 214–225. DOI: 10.3109/09286586.2015.1037401. 
25. Taylor, H.R. 2008. Trachoma: a blinding scourge from the bronze age to the twenty-
first century. South Yarra, Australia. Haddington Press. Chapter 6. 124. ISBN: 
9780975769591 (hbk.). Available: 
http://iehu.unimelb.edu.au/__data/assets/pdf_file/0009/719649/Trachoma_Book_HR
Taylor.pdf  [2016, July 10]. 
26. Tellis, B., Keeffe, J. E. & Taylor, H. R. 2006. Surveillance Report for Active Trachoma. 
National Surveillance and Reporting Unit, Annual Report. 31 (4) 366-374. Available: 
http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3104-pdf-
cnt.htm/$file/cdi3104b.pdf [2016, July 10]. 
27. The Nigeria National Blindness and Visual Impairment Survey. 2005-2007. Available: 
http://pbunion.org/Countriessurveyresults/Nigeria/Nigeria_survey_Summary_report.p
df [2016, July 19]. 
28. Thylefors, B., Dawson, C. R., Jones B. R., West, S. K., Taylor, H. R. 1987. A simple 
system for the assessment of Trachoma and its complications. Bulletin of the World 
Health Organization. 65 (4): 477-483. Available: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2491032/pdf/bullwho00075-0054.pdf  
[2016, July 10]. 
29. World Health Organization (WHO). 2003. Report of the 2nd Global Scientific 
Meeting on Trachoma. Geneva, 25-27. Available: 
http://www.who.int/blindness/2nd%20GLOBAL%20SCIENTIFIC%20MEETING.pd
f. [2018, June 5]. 
 
29 | P a g e  
 
30. World Health Organisation. 2009. Neglected Tropical Diseases Hidden Successes, 
Emerging Opportunities. WHO Press. 
Available:http://whqlibdoc.who.int/publications/2009/9789241598705_eng.pdf 
[2016, July 9]. 
31. World Health Organisation. 2013. Report of the 17th Meeting of the WHO Alliance 
for the Global Elimination of Blinding Trachoma.20-21. 
Available: www.who.int/blindness/publications/GET17Report_final.pdf  [2016, July 
19]. 
32. World Health Organization. 2013. Global Alliance for the Elimination of Blinding 
Trachoma (GET) by 2020. Weekly Epidemiological Record. 24 (88): 242–251. 
Available: http://www.who.int/wer/2013/wer8824.pdf  [2016, July 9]. 
33. World Health Organization. 2014. Key Trachoma Facts and Statistics. International 
Coalition for Trachoma Control.  Weekly Epidemiological Records.  Available: 
http://www.trachomacoalition.org/trachomastatistics [2016, July 11]. 
34. World Health Organization & United Nations International Children’s Emergency 
Fund (WHO/UNICEF) 2006. Core Questions on Drinking water and sanitation for 
household surveys. 1-25. Available: 
http://www.who.int/water_sanitation_health/monitoring/jmpfinal.pdf [2016, July 23]. 
35. World Health Organization (WHO). 2017. Morocco eliminates trachoma – the 
leading infectious cause of blindness. Available:  
http://www.emro.who.int/media/news/morocco-eliminates-trachoma-the-leading-
infectious-cause-of-blindness.html   [2017, May 15]. 
 
30 | P a g e  
 
36. Yalew N. K., Mekonnen, M. G &Jemaneh, A. A. 2012.Trachoma and its determinants 
in Mojo and Lume districts of Ethiopia. Pan- African Medical Journal. 13(1):8. 
Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587019/ [2016, July 11]. 
 
 
1 | P a g e  
 
PART B: LITERATURE REVIEW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 | P a g e  
 
1.0 Objectives of Literature Review 
The main aim of this study is to ascertain the prevalence of trachoma as well as the common 
household level and environmental risk factors for the disease in Benue state, Nigeria. To 
contextualize the study, a literature review was conducted on the research topic with an objective 
to synthesize and summarize existing literature on the global trends in trachoma burden with 
particular focus on its prevalence in Africa and specifically in Nigeria-Benue state as well as the 
risk factors associated with it. Finally, the review will identify gaps in the literature which will 
form the bases for this study. 
2.0 Literature Search Strategy 
The literature search focused on studies that reported on Trachomatous inflammation Follicular 
and Trachomatous Trichiasis prevalence among children and adults respectively. Key words and 
MeSH terms were generated and used to search for literature in the following online databases: 
Academic OneFile, Academic Search Premier, CINAHL via EBSCOhost, Cochrane Library, 
EBSCOhost, Eric, Google Scholar, Medline via PubMed, PubMed Central, Science Direct, 
SciELO and SCOPUS. The following key words were used appropriately to search for relevant 
literature in the various databases: Prevalence, Trachoma, Trachoma Infection, Child, Adult, 
Trachomatous Follicular, Trachomatous Trichiasis, Risk factors, Household Latrine, Water, 
Sanitation, Hygiene, Blindness, Epidemiology, Nigeria and Benue State. Additionally a general 
Google search was conducted to access available “grey” literature. Experts in the field of trachoma 
control were contacted for their expert input. The literature search also included a search through 
the reference list of downloaded peer reviewed articles to find additional relevant literature to be 
included in the review. Relevant studies conducted in all languages were selected initially based 
their titles and abstracts review. Full papers regardless of year of publication, were downloaded 
and reviewed to assess their quality.  
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3.0 Summary and Interpretation of Literature 
3.1 Background 
Trachoma is the most common contagious cause of avoidable blindness worldwide (Resnikoff et 
al., 2002; Pascolini & Marioti, 2011) associated with significant contribution to personal, societal 
and economic burden through blindness and vision impairment (West et al., 2013). It is a chronic 
conjunctivitis (Muhammad et al., 2015) initiated in early childhood by repeated conjunctival 
infection with the bacteria Chlamydia trachomatis.  
The most recent estimates reported by the WHO indicate that about 200 million people still live in 
trachoma endemic areas in 42 countries worldwide, 1.9 million people are blind or visually v 
impaired and about 3.2 million have TT and are at risk of going blind (Ramadhani et al., 2016; 
WHO, 2016) while approximately 1.2 million of the visually impaired are irreversibly blind 
(WHO, 2013).  
Trachoma is spread by direct contact with eye and nose discharges from infected individuals or by 
contact with fomites (inanimate objects that carry infectious agents) such as towels and/or wash 
cloths. Eye-seeking flies, which are attracted to eye and nasal secretions on the faces of infected 
children, are also believed to be vectors and are a major route of mechanical transmission of the 
bacteria (WHO, 2013).  
Infection with the bacteria triggers an immune response characterized by redness of the eye and 
discharge as well as inflammatory thickening of the tarsal conjunctiva and development of follicles 
(whitish inflammatory elevations) within the conjunctiva (Rabiu et al., 2012).  Repeated bouts of 
inflammation from cycles of infection and reinfection results in scarring of the  tarsal conjunctiva, 
forcing the eyelids and by extension  the eye lashes to turn inwards (entropion and trichiasis). 
Inward turning of the lashes exposes the corneal epithelium and the conjunctival surface to 
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continuous touching and rubbing by the in-turned lashes. Without preventive surgery, and with 
continuous rubbing of the cornea by the stray lashes, the abrasions coupled with secondary 
infections of the cornea from the TT then leads to irreversible blindness (Hu et al., 2010; Burton 
& Marbey, 2009).  
Despite projections in 2011 that blindness from trachoma will decrease significantly over a period 
of 5 years (Courtright & Lewallen, 2011), six years on, the condition still remains a major cause 
of avoidable vision loss and a significant public health problem in many parts of the world even 
though significant strides have been made to achieve the projected reduction in its prevalence. 
Trachoma is a disease that is known to be highly correlated with poverty, lack of personal and 
community hygiene, limited access to health care and water and for that matter it has been reported 
to be most prevalent in poor, under privileged communities of Sub-Saharan Africa, Asia, some 
parts of Latin America, the Middle East, the Western Pacific and in some deprived communities 
in Australia (Rabiu et al., 2012; Mariotti, Pascolini & Rose-Nussbaumer, 2009; Tellis, Keeffe & 
Taylor, 2006) where reports show that poverty, overcrowding, poor personal and environmental 
hygiene, inadequate water supply and low socio-economic status play favorable roles  as well as  
serving as direct channels through which trachoma is transmitted from person to person (Ejere, 
Alhassan & Rabiu, 2015).  
Although trachomatous blindness is untreatable, it is clearly preventable. WHO has decided to 
lead the effort to prevent avoidable blindness from trachoma by the year 2020.  Efforts to eliminate 
trachoma, as a public health problem and a significant avoidable cause of blindness, have therefore 
revolved around a comprehensive approach recommended by the WHO known as the “SAFE” 
strategy (Emerson et al., 2006). For effective planning implementation and evaluation of trachoma 
elimination programmes, WHO has set out targets that must be achieved in terms of the prevalence 
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estimates of trachoma in the endemic districts so that programme implementers can know when to 
stop some aspects of the elimination strategy such as the Mass Drug Administration (MDA) 
campaigns, this the WHO termed Ultimate Intervention Goals (UIG) (WHO, 2003). However for 
the strategy to be effective, the distribution of trachoma must be known through district level 
prevalence surveys (WHO, 2013; Polack et al., 2005).  
The prevalence of blindness in Nigeria is one of the highest in Africa with over 80% of blindness 
due to avoidable causes (Abdull et al., 2009). Inspite of this alarming rate of blindness in Nigeria, 
blindness prevalence data are available for only a few communities. This literature review is aimed 
at contextualizing the Global Trachoma Mapping (GTMP) survey conducted in Benue State 
Nigeria between April and September 2014 according to WHO stipulated standards (Solomon et 
a 2015) to produce data that will be used to generate prevalence estimates needed to plan 
elimination of trachoma in Benue state of Nigeria and also to further help complete the Global 
Atlas of Trachoma (GAT).  
4.0. Individual and Environmental Risk Factors for Trachoma 
4.1. Lack of potable water 
One of the most sited reasons for trachoma transmission from lack of personal hygiene is the 
unavailability of potable water for basic household and personal use. There have been reports that 
lack of water sanitation and hygiene, to some extent favors trachoma transmission especially 
among vulnerable rural poor populations who do not also have the benefit of antibiotic treatment 
for chlamydia trachomatis infections (Traverse et al., 2013). Water scarcity may promote trachoma 
transmission owing to less water availability for households to use for face washing, washing of 
dirty cloths, washing of hands after visiting the latrine as well as for other personal hygiene 
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practices. Unclean environments provide more effective breeding sites for eye-seeking flies and 
also promotes festering of other conditions responsible for transmission of trachoma infection.  
4.2. Distance to and type of water source 
Another significant factor relating to water availability has to do with the distance to water source. 
It has been shown that families who walk more than 30 minutes distance to get water are more 
likely to have trachoma compared to those who embark on a less than 30 minutes’ walk to water 
bodies to get their water (Ketema et al., 2012; Malhotra et al., 2016). The relationship between 
distance to water source and the prevalence of trachoma infection has been rather a controversial 
one. Several studies have indeed found an association between increased distance to water source 
and the prevalence of active disease (Taylor et al., 1989; West et al. 1989; Schémann et al. 2002; 
Ketema et al., 2012). However another study did not support that claim (West et al., 1991). 
According to reports by Hu et al, this finding may be explained by the presence of what they 
referred to as “water use plateau” “in which per capita water consumption between households 
often seems to be constant when the round trip to collect water is below a threshold of around 30 
min”. They therefore argued that the quantity of water brought into a household may be more 
important than the distance to water source (Hu et al., 2010).  
4.3. Clean face 
 A recent study by Muluneh and colleagues posited that facial hygiene has a positive effect on the 
reduction of the risk of trachoma. They also noted that at least once a day facial Water, Sanitation 
and Hygiene (WaSH) practice with soap enhances the effectiveness of reducing trachoma risk 
(Muluneh, Zewotir & Bekele, 2016). Mengistu et al also found that facial cleanliness of children 
was significantly associated with trachoma so much so that those children with unclean faces were 
two times more likely to develop trachoma compared to those children with clean faces (Mengistu 
et al., 2016). Frequency of face washing has been associated with trachoma (Jip et al., 2008), even 
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though experts advocate washing face at least once a day, washing ones face at least twice per day 
was found to be more favorable in reducing trachoma compared to at least once. 
4.4. Practice of good WaSH habits  
To improve the standard of living of a population, supply of safe drinking Water, Sanitation and 
Hygiene (WaSH) are fundamental necessities. This has a direct bearing on several aspects of 
human life including the protection of health and the environment, which can lead to improved 
educational outcomes, greater convenience and socio-economic status (Hutton & Chase, 2016). It 
is often common for communities with high levels of poverty to have challenges with meeting the 
needs of WaSH. Good WaSH practices are essential in reducing the prevalence of infectious 
diseases including trachoma. For instance a study in Ethiopia has shown that in major towns where 
sanitation status and water supply is relatively better, the prevalence of active trachoma was very 
low (Berhane et al., 2007) while high  prevalence of active trachoma was recorded in areas where 
water supply and sanitary conditions were poor.  
4.5. Age 
Age is also a significant determinant of trachoma infection (Shiferaw & Moges, 2013).  Trachoma 
infection (TF) usually starts in childhood with age 4-6 known to be the age within which the 
greatest incidence rates of infection have been observed according to some studies (Ketema et al., 
2012) while other studies cite age 1-5 as the most critical for trachoma infection (Asres et al., 
2016). Children have been shown to be the most susceptible to trachoma infection due to their 
natural tendency for close contact activities and frequent face-rubbing (WHO, 2013). The 
predominance of trachoma within the 1-5 age bracket has been attributed to the fact that children 
within this age group are mainly preschool children who cannot care for themselves, they have 
more contacts, play close together and have little knowledge about practices that favor trachoma 
transmission (Asres et al., 2016). It is important to note that some studies have also reported age 
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6-10 as the most critical age group for trachoma infection (Goldschmid et al., 2007). Though these 
reports could be valid, they are however not consistent with the widely reported age group range 
of 1-5 (Edwards et al., 2012; Asres et al., 2016) and this may possibly be because these studies 
were not standard WHO studies hence the discrepancy in the findings.  
4.6. Gender 
Gender has always been a factor in the prevalence of trachoma. Several studies have reported extra 
burden of trachoma among women compared to men (Asres et al., 2016; Mengistu et al., 2016; 
Xue et al., 2016; Courtright et al., 1989). Studies showing the distribution of trachoma signs by 
gender indicate that active trachoma which includes both TF and TI is slightly more common 
among girls (13.5%) than in boys (12.4%) (Noatina et al., 2013).  
In a review on the contribution of sex-linked biology and gender roles disparities in trachoma 
distribution, Courtright and West enumerated several factors that could explain the seemingly huge 
burden of TT among women compared to men (Courtright & West, 2004). Using research findings 
from Tanzania as well as other parts of the industrialized world, they examined a number of 
hypothesis on factors that make females biologically more susceptible to TT. Hormonal changes, 
heavy bacterial load, greater likelihood of persistent infections, higher possibility of conjunctival 
scaring, women’s role as primary care givers to children as well as certain practices such as the 
use of Kohl among some Islamic women exposed them to frequent scaring of the tarsal conjunctiva 
and hence TT. It was however difficult to confirm or dispute some of these hypothesis due to lack 
of appropriate data and research findings. 
4.7. Access to latrine 
Limited access to latrines or distance of latrine from household increases the possibilities of fecal 
contamination of the environment thereby increasing the density and providing breeding material 
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for the fly Musca sorbens, which has been heavily implicated in trachoma transmission (Mengistu 
et al., 2016). Results from the study by Alemayehu and colleagues revealed that the odds of active 
trachoma among children who were from households without latrines were 4 times the odds of 
children from households without latrines (Alemayehu et al., 2015). Latrine access has been found 
to be associated with a lower risk of trachoma. In a recent study by Muhammad et al, access to 
latrine was found to be a significant protective measure against trachoma infection (Muhammad 
et al., 2015). The protective effect of latrine access on trachoma prevalence was attributed to the 
fact that with the availability of latrines there is constant removal of fecal material from the 
environment leading to a smaller fly population (Emerson et al., 2004; Hu et al., 2010). Using pit 
latrines for example may decrease the possibility of fly breeding in the area around the household 
and hence the fly density (Muluneh, Zewotir & Bekele., 2016). Several other studies have found 
this relationship between trachoma infection and latrine assess to be true (Abdou et al., 2007; 
Mpyet et al., 2012) while others found not so much significant association (Muluneh, Zewotir & 
Bekele., 2016). This discrepancy was explained by possible interaction and for that matter 
collinearity between the variables compared in the survey.  
4.8. Vectors 
The fly Musca sorbens, a vector of trachoma, has been known to prefer human feces and cattle 
dung as a breeding media (Alemayehu et al., 2015). The presence of flies on the face, among other 
findings like a dirty face, and the presence of animal dung in the compound of residence have also 
been found by Mpyet et al, to be independent risk factors for active trachoma among children in 
Kano State (Mpyet et al., 2012).  
5.0. Control Initiatives and Strategies 
According to King et al, the current threshold for intervention with the SAFE strategy at district 
level is a prevalence of trachomatous inflammation follicular (TF) in children 1–9 years old of ≥ 
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10% (WHO, 2014). WHO also recommends a community-by-community approach to assessment 
and intervention for district-level prevalence of < 10%. They further suggested that the target 
prevalence by which mass antibiotic interventions to control trachoma can be ceased is < 5% TF. 
WHO has therefore encouraged countries to show a prevalence of < 5% TF for at least 3 years 
after interventions have ceased in order to achieve elimination status (WHO, 2014). For 
trachomatous trichiasis WHO stipulates the threshold to be a prevalence of  TT “unknown to the 
health system” of less than 0.2% in adults aged 15 years and older (WHO, 2003). 
The simplified grading system developed by Thylefors and colleagues has been very useful in 
trachoma elimination. According to the grade descriptions, Trachomatous inflammation – 
Follicular (TF) represents the presence of five or more follicles (each >0.5 mm in diameter) in the 
upper tarsal conjunctiva, Trachomatous inflammation – Intense (TI) is recorded if there is 
pronounced inflammatory thickening of the tarsal conjunctiva that obscures more than half of the 
deep normal vessels, similarly  Trachomatous Scarring (TS) is the presence of scarring in the tarsal 
conjunctiva while Trachomatous Trichiasis (TT) represents the presence of at least one lash 
rubbing on the eyeball and lastly Corneal Opacity (CO) represents an easily visible corneal opacity 
over the pupil (Fig 1. Appendix F) (Thylefors et al. 1987) 
5.1. Vision 2020 
Vision 2020 “The right to sight” is a global initiative launched in 1999 by the WHO. The initiative 
was a  joint programme of the WHO and the International Agency for the Prevention of Blindness 
(IAPB)  aimed at eliminating all avoidable causes of blindness by the year 2020 (WHO/IAPB, 
1999). WHO sees vision as a fundamental human right and therefore believes all persons should 
be able to receive quality affordable eye care and have the right to sight. The goal of Vision 2020 
was therefore to enable individuals to access vision as a critical component of their fundamental 
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human rights (Muhammad & Adamu, 2014). Reports by Muhammad and Adamu has shown how 
the VISION 2020 initiative has been beneficial in raising awareness concerning blindness 
(Muhammad & Adamu, 2014).  
5.2. Global alliance for the Elimination of Trachoma (GET 2020)  
In 1999, the World Health Assembly of the WHO passed a resolution to galvanize efforts in order 
to eliminate preventable blindness from trachoma by the year 2020 (WHO, 2012). This led to the 
launch of the initiative that has come to be known as Global Alliance for the Elimination of 
blinding Trachoma by the year 2020 (GET 2020) (Emerson et al., 2006). The GET 2020 initiative 
was championed by the WHO and the IAPB, a consortium of non-governmental organizations and 
the health services of member countries. It consists of over 32 signed-up and committed member 
countries who meet annually to assess and discuss progress and also share new research 
developments and techniques that could then be translated into policy and practice to further 
promote the course of the initiative in member countries. The organizations have therefore 
endorsed, recommended and promoted an integrated strategy known as the “SAFE” strategy aimed 
at treating and preventing trachoma from causing unnecessary blindness. The SAFE strategy is a 
comprehensive programme consisting of the following control measures: Surgery for 
entropion/TT; Antibiotics for infectious trachoma; Facial cleanliness to reduce transmission; and 
Environmental changes such as control of disease-spreading flies and access to clean water and 
latrine (WHO, 2012). 
6.0. Trachoma Burden in Africa 
The burden of blindness in Sub-Saharan Africa has been touted to be the greatest of all the other 
regions of the world. It is reported that the region contains less than 10% of the world’s population, 
yet about 20% of the world’s blind are located in the region (Thylefors et al., 1995; Yalew, 
Mekonnen & Jemaneh, 2012). In going through the literature, a number of studies have reported 
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on blindness within the African region. Studies in Cameroon have suggested that blindness 
prevalence in persons 40 years and above was between 1.1% to 1.4% (Oye et al., 2006). Similarly, 
reports from blindness surveys in Kenya have indicated a blindness prevalence in persons 50 years 
and above to be 2.0% (Mathenge et al., 2007). Lawan et al conducted a blindness prevalence survey 
in northern Nigeria, and found a blindness prevalence among all age groups to be  1.14% (Lawan 
et al., 2002) while in a previous study by  Rabiu and colleagues among persons 40 years and above, 
the prevalence was 8.2% (Rabiu, 2001). Blindness prevalence in southern Nigeria though lower, 
its impact becomes more significant when considered among whole populations. The prevalence 
of blindness range from 9% in rural southern –western Nigerian populations (Adeoye, 1996) to 
1.2% (Adeoti, 2004) in tropical African populations. In a sharp contrast to the situation of blindness 
in the African region, countries with established market economies account for 15% of the global 
population but only 6% of the world’s blind can be found in these populations (Thylefors et al., 
1995; Yalew, Mekonnen & Jemaneh, 2012).  
Not only is the burden of blindness in the sub-Saharan African region the worst in the world but 
also reports show that 75% of all blindness in mostly developing countries in this region are from 
preventable diseases such as trachoma which can either be prevented or cured (Mengistu et al., 
2016). In fact reports by Polack et al suggest that in the Sahel region, 100% of blindness observed 
was avoidable (Polack et al., 2005). It is further reported that more than half of all the districts that 
are suspected to be trachoma endemic are in Ethiopia and Nigeria alone (Kalua et al., 2014).   
In Ethiopia, for instance the national prevalence of active trachoma for children between ages 1-9 
was 40.1% (Berhane et al., 2007).  National prevalence of TT was 3.1% among persons 15 years 
and above. Additional mapping surveys done in Nigeria (Mpyet et al., 2012; Mpyet, Ogoshi & 
Goyol, 2008; King et al., 2009), Ethiopia (Ketema et al., 2012), Cameroun (Noatina et al., 2013), 
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Mali (Schémann et al., 1998), South Sudan (Edwards et al., 2012), North Western Ethiopia 
(Shiferaw & Moges, 2013), Guinea Bissau (Last et al., 2014) and in Malawi (Kalua et al., 2015) 
have all shown high trachoma prevalence rates especially for TF among children 1-9 years old, 
with TT prevalence almost always being less than 3% in these countries  except in the case of 
Eastern Equatorial and Upper Nile States of Southern Sudan where a study by  Ngondi et al 
reported an overall  TT prevalence among persons 15 years and above  of 9.2% in 2005. The 
highest TT prevalence of 17.0% was found in one of the study communities (Ngondi et al., 2005).  
7.0. Gaps in knowledge and Conclusion 
The literature review has unearthed a number of challenges that befall trachoma elimination 
initiatives and most have to do with contradictions and inconsistencies in the evidence base 
especially with reference to the risk factors for the disease. For example while some studies have 
suggested that trachoma, both TF and TT are more common in women (Asres et al., 2016; 
Mengistu et al., 2016; Xue et al., 2016; Cromwell et al., 2009; Mpyet, Ogoshi & Goyol, 2008), 
other studies such as one by Malhotra et al suggest that there was no sex predilection for presence 
of TF and TT (Malhotra et al., 2016). Indeed some other studies have also found no gender 
differences in prevalence of active trachoma (Harding –Esch et al., 2008). Additionally Berhane 
et al in their national survey of blindness in Ethiopia found no marked gender difference in the 
prevalence of active trachoma (Berhane et al., 2007). Other studies found no such gender 
difference in trachoma prevalence among adults except among children below 10 years of age 
(Ngondi et al., 2005).  
Another challenge observed through this review was the fact that most of the studies reporting on 
trachoma were observational studies. Though most of these observational studies especially on the 
environmental interventions for reducing trachoma infection in communities, suggested a potential 
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benefit, they most often suffer several validity challenges (Rabiu et al., 2012) while some recent 
studies also produced inconsistent results (Ejere, Alhassan & Rabiu, 2015). 
Adequate knowledge of trachoma prevalence at district level is particularly important in planning 
the national trachoma control program in order to achieve the goal of eliminating trachoma as a 
blinding disease by year 2020 (Ngondi et al., 2013). From the review, it was evident that further 
studies are needed in many areas to bridge this knowledge gap.  
With respect to the risk factors for trachoma, the evidence base is not unanimous hence the need 
to conduct further studies with standard WHO guidelines to be able to generate credible evidence 
to add to the already existing evidence. For example in terms of latrine use to control fly density 
to reduce trachoma infection, despite evidence from some studies suggesting that the 
implementation of a household latrine promotion project is acceptable, feasible and has potential 
to control trachoma prevalence (Diallo et al., 2007), a systematic review by Rabiu et al., found that 
several studies on latrine provision as a fly control measure did not demonstrate any significant 
trachoma reduction potential (Rabiu et al., 2012). A similar study by Haile et al also came to similar 
conclusions (Haile et al., 2013). In the review by Rabiu et al, apart from the reports on latrine 
provision as a fly control mechanism, other hygiene and environmental factors were also reviewed 
and were found to be insignificant in  controlling trachoma. The reports on health education and 
its effectiveness in eliminating trachoma was contradictory between studies reviewed.  
Studies by Kalua et al found that hygiene and environmental factors were not significant in 
controlling trachoma prevalence (Kalua et al., 2014) indeed with regards to risk factors for 
trachoma, only the presence of a dirty face was associated with TF in this study. It is however 
important to note that in most of these studies with negative results, serious challenges were raised 
about sample size. For example in one of such studies, the latrine survey was performed in a sample 
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of 10 households per community, reducing the certainty of the latrine use estimates (Haile et al., 
2013).  
While experts are advocating for action from governments, NGOs, private sector and all other 
health professionals to support and expand the SAFE strategy to combat trachoma, (Mariotti,  
Pascolini, Rose-Nussbaumer, 2009), the evidence upon which these stakeholders can make 
decisions on trachoma elimination is significantly lacking. 
In order to develop more robust estimates of the burden of trachoma, there needs to be a 
coordinated effort to conduct population-based surveys with a national sampling frame in 
representative countries from endemic regions (Burton, & Mabey, 2009). 
Despite the wealth of evidence on the prevalence and risk factors for trachoma, many of the studies 
that adduced these evidence had some limitations in various departments such as their conduct, 
method of analysis, method and criteria for sample size selection (King et al., 2009) period of 
study conduct, time of day study was conducted, overall participation rate (Noatina et al., 2013) 
and other factors that impacted on the results of the studies. This variability in quality and 
methodology, made it difficult for all studies to be compared to ascertain the quality of the 
evidence (Smith et al., 2013; Polack et al., 2005). For instance for studies that reported on the 
availability of water and its impact on trachoma prevalence, the results could not be said to be a 
true representation of the situation if the study was done in the rainy season when it is likely to 
rain and therefore make water readily available in this period when in actual fact there may be 
significant challenges with water in the dry season in such a study area (Rog et al., 2011).  
In the survey in Jigawa state the study was limited by the lack of full population data on sex and 
age, which did not allow for calculation of age-sex adjusted prevalence values for the study 
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population (Ramyil et al., 2015). Another factor that can affect participation for any trachoma 
survey is the time of day the study is done. Pre-school children are more likely to be sampled if a 
study is done at a time of the day when most children of school going age are likely to be in school. 
Studies done on farm days in certain communities are likely to miss out on adults above 15 years 
because they may be on their farms at the time the study will be conducted. These scenarios can 
create a potential for over estimation of TF and TT prevalence if many persons under age 15 or 
more persons over the age 15 respectively were not present at home to be examined (Ngondi et 
al., 2005). 
Some studies also used small and variable (Polack et al., 2005) sample sizes leading to wide 
confidence intervals and hence imprecise estimates in addition to the fact that very important 
confounding factors were not considered or inadequately controlled for (Muhammad et al., 2015) 
as well as some studies using non-random sampling techniques leading to results not being 
representative of the entire population (Agarwal et al., 2016).  
With respect to the association between water and trachoma prevalence, the review revealed that 
lack of evidence of the association between water access and trachoma may be due to the low 
number of available studies (Stocks et al., 2014). Low coverage was a challenge in some studies 
(Mpyet, Ogoshi & Goyol, 2008). A situation which can significantly affect the validity of the 
results of the studies. The GTMP provided an opportunity for standard WHO recommended 
surveys to be conducted with mechanisms and procedures that will invariably rise above some of 
the numerous challenges unearthed in the review of the existing literature. One such surveys was 
conducted in Benue state of Nigeria on which bases this current study is being conducted. 
In respect of the above mentioned challenges and gaps in the literature relating to trachoma 
prevalence and its risk factors, this study is being conducted with the main objectives of 
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determining the prevalence of trachoma and the common risk factors associated with the disease 
in Benue State, Nigeria.  
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ABSTRACT 
Purpose: To determine the prevalence of trachoma and the common environmental risk 
factors associated with the disease in each Local Government Area (LGA) of Benue state, 
Nigeria. 
Methods: Two-stage cluster-sampling was used to conduct a series of 23 population-based 
prevalence surveys. LGAs were the evaluation units surveyed. In each LGA, 25 households 
were selected in each of 25 clusters, and individuals aged one year and above resident in 
those households were invited to be examined for trachoma. Data on access to water and 
sanitation were also collected at household level. 
Results: A total of 91,888 people were examined from amongst 93,363 registered residents 
across the 23 LGAs. The LGA-level prevalence of trachomatous inflammation—follicular 
(TF) in 1–9-year-olds ranged from 0.3–5.3%. Two LGAs had TF prevalences of 5.0–9.9%. 
The LGA-level prevalence of trichiasis in ≥15-year-olds ranged from 0.0–0.35%. Access 
to improved drinking water sources ranged from 0% in Gwer West to 99% in Tarka, while 
access to improved sanitation ranged from 1% in Gwer West to 92% in Oturkpo. Adults 
≥15 years were 8.94(95%CI: 2.79 – 29.64) times more likely to have Trichiasis compared 
to persons between 1-9 years of age 
Conclusion: There is need for public health-level interventions against trachoma in three 
LGAs of Benue State. 
Key words: trachoma, trichiasis, epidemiology, Nigeria, Benue State, Global Trachoma 
Mapping Project 
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INTRODUCTION 
Trachoma is the world’s number one cause of infectious blindness.1 The disease, caused by  
repeated bouts of infection by the obligate intracellular eubacteria Chlamydia trachomatis, 2 which 
passes from person to person through contaminated hands, clothes and vectors such as the eye-
seeking fly, Musca sorbens.1 Trachoma normally begins in childhood as an inflammation of the 
conjunctiva but worsens with time, reinfection and eventually leads to scaring of the upper tarsal 
conjunctiva which by extension causes the eyelashes to turn-in and rub on the cornea until it 
becomes scared,  cause corneal damage and irreversible blindness.1 Trachoma has been eliminated 
from many developed countries several years ago, however it continues to be a public health 
problem in many African countries including Nigeria.3, 4  
Recent reports by the World Health Organization (WHO) suggests that trachoma is endemic in 42 
countries worldwide with about 200 million persons living in trachoma endemic areas and are at 
risk of trachoma infection, with about 50% of this number living in Ethiopia, Malawi and Nigeria 
alone.1  
WHO has been at the forefront of the fight to eliminate trachoma as a public health problem by 
the year 2020 through its flagship initiative “Global Elimination of Trachoma” (GET2020) 
established in 1996.35 It has therefore recommended the implementation of a comprehensive 
strategy which goes by the acronym “SAFE” (Surgery, Antibiotics, Facial cleanliness and 
Environmental change) strategy 5 based on the prevalence estimates of TF(Trachomatous 
Follicular)  among children 1-9 years old and TT(Trachomatous trichiasis) among adults 15 years 
and above.4  
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WHO recommends use of the SAFE strategy until elimination threshold prevalences (trichiasis 
<0.2% in ≥15-year-olds and TF <5% in 1–9-year-olds) are reached in each formerly-endemic 
district.4, 6 
From 2012–2016, members of the WHO Alliance for GET2020 made considerable progress in 
baseline mapping of suspected trachoma-endemic districts worldwide within the Global Trachoma 
Mapping Project.1, 36 Its goal was to provide a complete picture of the global burden of trachoma, 
enabling all stakeholders to see where work was needed to achieve elimination as a public health 
problem.37 Though many other states of Nigeria had previously been mapped for trachoma,3 no 
population-based surveys had been undertaken in Benue State, despite the fact that SAFE 
interventions had been required in neighboring Nasarawa State, including in a number of bordering 
Local Government Areas (LGAs).3 
The work described here was therefore conducted as part of the WHO Global Trachoma Mapping 
Project (GTMP) in 2014 to (a) the LGA level prevalence of trachoma (b) determine LGA-level 
prevalence of access to improved water and sanitation; and (c) estimate the likely number of doses 
of antibiotics and number of people to be managed for trichiasis in Benue state of Nigeria in order 
to reduce the prevalence estimates below the elimination threshold. 
MATERIALS AND METHODS 
Study design and setting 
The planning and conduct of the GTMP survey in Benue state of Nigeria between April and 
September 2014, followed the standard GTMP procedures as described elsewhere.8 Benue state is 
located in the north– central zone of Nigeria with a population of about 4.2 million and a land area 
of 34,059 square km. 50% of the population are females while 34% is between 0-9 years old. The 
population includes a diverse number of ethnic groups distributed in 23 different districts (LGAs).9 
 
6 | P a g e  
 
Sampling and procedure 
As already described, 8 villages were used as clusters, of which 25 were selected from each of the 
23 LGAs in Benue state using a 2-stage cluster random sampling approach and a probability 
proportional to the village population size technique. From each village 25 households were 
selected. Taking into consideration the need to report expected TF prevalence of 10% and a 95% 
confidence interval with absolute precision of 3%, a minimum of 384 children aged 1–9 years 
selected by simple random sampling would be required. This number was however adjusted by a 
design effect of 2.65 and was further inflated by a factor of 1.2 to account for non-response rate to 
arrive at a final minimum sample size of 1019 children aged 1-9 in the eligible sample population. 
Enough participants were selected with the hope of capturing enough adults 15 years and above in 
order to report on trichiasis prevalence. 
Despite challenges about its accuracy, 10 the random walk technique was employed in selecting 
which households to examine. With the help of a resident, the center of a village was located and 
a direction was randomly selected by spinning a pen, all residents 1 year and above residing in 
households along this direction were selected and examined upon their consent, by GTMP-
certified graders for signs of trachoma using standard WHO (World Health Organization) 
recommended simplified grading systems, 11 practices and equipments.  Information on potential 
individual and household-level environmental risk factors for trachoma was obtained through 
household heads’ responses to questions on a pre-validated WaSH (Water Sanitation and Hygiene) 
structured questionnaire of the WHO/UNICEF(United Nations Children’s Emergency Fund) Joint 
Monitoring Programme 12 administered by the survey team through a structured interview session.  
Data collected on each participant included age, gender, household characteristics, drinking water 
source, distance to drinking water, washing water source and distance to washing water, latrine 
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facility, condition and distance of latrine facility from household, water and soap availability in 
latrine facility. Even though information was obtained about all the grades of trachoma, for 
planning and epidemiological purposes, this study focuses on and reports only the prevalence of 
TF among children aged 1-9 years and trichiasis among persons ≥ 15 years as our primary outcome 
measures.  Interrater variability was ensured by certified experienced trachoma graders. 
Operational definitions 
Five or more follicles, each at least 0.5mm in diameter, in the central part of the upper tarsal 
conjunctiva indicates TF, while trichiasis was the presence of at least one eyelash touching the 
eyeball or evidence of recent removal of in-turned eyelashes.11 Visual inspection of household 
latrine and hand washing facilities was also carried out to obtain information on “improved” water 
source and sanitation conditions in each household. Similarly Information on availability of water, 
source, latrine facility and sanitation practices at latrine facility were obtained from participants in 
accordance with guidelines in the WaSH report12 and the responses were coded accordingly as 
previously described.8 Trachoma was not considered a public health problem if TF prevalence in 
children 1-9 years old falls below 5% and the prevalence of TT is <0.1%13,27 However in LGAs 
where trichiasis prevalence was higher than the elimination threshold of <0.2% in persons ≥15 
years, steps were taken to calculate the number of trichiasis surgeries needed to be conducted to 
reach this goal. 
Data management and analysis 
Data were checked and cleaned by an independent data manager, approved by the health ministry, 
then analyzed; outputs were again health-ministry approved.8 The approved data were imported to 
Stata version 14.0 for analysis. In Stata further checks were done to ensure data was clean and free 
from outliers, inconsistencies, inaccuracies, missing values as well as satisfying underlying 
assumptions of the intended statistical tests. Summaries as well as univariate and multivariate 
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analysis were conducted to ascertain the presence, strength and direction of any statistical 
association between the independent and dependent variables reporting crude (COR) and adjusted 
odds ratios (AOR), 95% Confidence Intervals (CI) and p-values. 
Cluster-level proportions of children with TF were adjusted for age in 1-year age bands, and 
proportions of adults with trichiasis were adjusted for gender and age in 5-year age bands; local 
2006 census data9 were used for this adjustment process. LGA-level prevalences were calculated 
as the means of adjusted cluster-level proportions. Confidence intervals (CIs) were determined by 
bootstrapping: sets of 25 adjusted cluster-level proportions were selected, with replacement, over 
10,000 replications, then the 2.5th and 97.5th percentiles of the ordered means of those sets formed 
the lower and upper bounds of the CI. 
Multi-variable logistic regression model was fitted using all the variables except the ones suspected 
of breaking the principles of multicollinearity. The final model was fitted using pre-determined 
variables adjusting for gender, age, clustering as well as other relevant variables. A p-value of 
<0.05 was considered statistically significant.  
Ethical Considerations 
The survey was approved by the Ethics Committee of the London School of Hygiene and Tropical 
Medicine (reference number: 6319) and the National Health Research Ethics Committee of Nigeria 
(reference: NHREC/01/01/2007) while the government of Benue state Ministry of health gave 
permission for the conduct and appropriate report of the study. Additionally, the study was 
approved by the University of Cape Town Institutional Review Board (IRB) (reference: 
IRB00001938). Written and/or verbal informed consent was appropriately obtained from subjects/ 
guardians. Examination, data collection and management procedures conformed to the guidelines 
and tenets of the Declaration of Helsinki32. All the data collected were stored on a purpose built 
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Open Data Kit -based Android Smartphone application (Links) 8, 14 encrypted during transport, 
and stored in a password-protected database in the cloud to ensure confidentiality, fidelity and 
accessibility.8, 14 Subjects who presented with active trachoma (TF) were given antibiotics; 33 those 
who needed trichiasis surgery were referred to the nearest provider.34 
RESULTS 
Sociodemographic characteristics 
A total of 93, 363 participants from Benue state were enumerated across the 23 LGAs; 91,888 
participated and were examined. 1,146 were not present to be examined while 602 refused 
participation. Overall, 49.33% (46,194) of persons enumerated were males while over half of them 
50.67% (47,442) were females.  97.81% and 98.44% of the enumerated males and females 
respectively were examined with their consent. The age of participants ranged from 1 year to 100 
years with an average age of 18.28 ±17.88. Age and sex distribution of the participants is shown 
in (Table 4).  
Access to water and sanitation 
More than half of all participants (57%) lived in households without a latrine facility, in which 
adult residents either defecated in the bush or in the open near the household. At LGA-level, the 
proportion of households with access to improved sanitation ranged from 1.38% in Gwer West to 
92.16% in Oturkpo. In only two of 23 LGAs did ≥80% of households have access to improved 
sanitation facilities, while only one (Tarka) of 23 LGAs had ≥80% of households with access to 
an improved water source (Table 8: Appendix E).   
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Table 4: Age and Sex distribution of survey participants, Global Trachoma Mapping Project, 
Benue state, Nigeria, April –September 2014. 
Age 
(years) 
Males Females   
 Number % Number % Total % of Total 
1-10 24,660 51.93 22,823 48.07 47,483 50.71 
11-20 8,219 49.28 8,458 50.72 16,677 17.81 
21-30 3,386 33.81 6,629 66.19 10,015 10.70 
31-40 3,061 40.35   4,525 59.65 7,586 8.10 
41-50 2,756 52.55 2,488 47.44 5,244 5.60 
51- 60 2,089 60.57 1,360 39.43 3,449 3.68 
61-70 1,251 61.29 790 38.71 2,041 2.18 
71-80 584 66.90 289 33.10 873 0.93 
80+ 188 70.15 80 29.85 268 0.29 
Total 46,194 49.33 47,442 50.67 93,636 100 
 
Prevalence of trachoma among children 1-9 years old and adults ≥15 years 
Overall (unadjusted) prevalence of TF among children 1-9 years old was 2.00% (95% CI: 1.20 – 
2.98). TF prevalence was higher among females 1.44% (95% CI: 1.33 – 1.56) compared to males 
1.16% (95% CI: 1.06 – 1.28). There was a statistically significant difference between TF 
prevalence among the two genders (p<0.001). At the LGA level, the average prevalence of TF 
among persons 1-9 years of age ranged from 0.3% to 5.3% (Table 6: Appendix E). 
A total of 38,802 persons 15 years and above were examined. There were 42 adults with trichiasis, 
giving an overall (unadjusted) prevalence of trichiasis in examined ≥15-year-olds of 0.11%. 
Prevalence of trichiasis was higher among females 0.05% (95% CI: 0.03 – 0.07) compared to 
males 0.03 %( 95% CI: 0.02 – 0.05) this was however not statistically significant (p=0.13). LGA 
level trichiasis prevalence ranged between 0.00% in 15 LGAs to 0.35% (0.12–0.50) in Okpokwu 
(Table 7: Appendix E). Two LGAs had TF prevalence among children 1-9 years old between 5%-
9.9%. Over 90% of the LGAs (21) had TF prevalence of <5% (Table 6: Appendix E). Over 90%% 
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(21) LGAs had trichiasis prevalence of less than 2 per 1000 (<0.2%) among adults (Table 4). From 
the results, it is estimated that the Benue state has a trichiasis backlog of 1,064. (Table 7: Appendix 
E). In the two LGAs with prevalence estimates of ≥0.2%, the estimated number of individuals 
needed to be managed to reduce the prevalence to less than the elimination threshold, ignoring 
incident disease and mortality in those with trichiasis, is 173. 
Household and environmental determinants of trachoma 
Overall, age, gender, latrine access, distance to drinking or face washing water source, presence  
and access to latrine facility as well as hygienic practices at latrine facility were independently 
associated with a greater odds of having trachoma. Upon adjusting for all these variables through 
the multivariate logistic regression, only age, sex, distance to drinking water source, presence of 
latrine facility and latrine accessibility significantly influenced TF occurrence. Multivariable 
analysis has shown that children who have TF were 1.74 times (AOR: 1.74 95%CI: 1.53 – 1.99) 
as likely to be between the ages of 1-9 compared to those who don’t have TF (Table 9: Appendix 
E). Similarly Residents who have TF were 1.22 times (AOR: 1.22: 95%CI: 1.08 – 1. 37) as likely 
to have difficulty accessing latrine facility compared to those who do not have TF and finally 
households with high prevalence of TF were 1.72 times (AOR: 1.72(95% CI: 1.09 – 2.70) as likely 
to travel distances more than 30 minutes to get drinking water compared to those who do not have 
TF (Table 9) Age was a major risk factor for trichiasis among adults 15 years and above. Persons 
who have trichiasis have 9 times (AOR: 8.94; 95% CI: 2.70 – 29.64) the odds of being 15 years 
and above compared to persons who do not have trichiasis. Absence of latrine facility in household 
was associated with a greater odds of trichiasis 4.39, (AOR: 4.39; 95%CI: 1.00 – 19.18). (Table 
10: Appendix E).  
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DISCUSSION 
Trachoma remains endemic in many parts of Nigeria 3, 4, 15   despite significant efforts put into 
“SAFE” strategy implementation programmes to eliminate the condition as a public health 
problem. The overall prevalence of trachoma (TF) among children 1-9 years old was 2% while 
trichiasis among persons 15 years and above was 0.11% in this study. Generally, the results show 
that trachoma was of lower prevalence in this state compared to other regions in Nigeria 3, 4, 18, 25 
and in the African sub-region16 despite inadequate coverage of water and sanitation facilities. 
(Table 8).TF prevalence of 2% observed in this study is lower compared to recent reports of 3.4% 
in Kano state.4, 25 At the LGA level, the results of TF prevalence in this study were similar to that 
of earlier studies. 18 
The relatively low prevalence of trachoma in Benue state compared to other parts of Nigeria may 
be attributed to difference in endemicity between the northern and north-central parts of the 
country as well as time of the study. This survey was conducted at a time when a lot of efforts 
have already been made to control trachoma in the states of Nasarawa and Plateau following a 
similar mapping project, 3 thereby preventing possible spread of the disease through migration of 
persons into Benue state from these highly endemic neighboring states. Despite the generally low 
prevalence levels, trachoma was a public health problem in Benue state of Nigeria per WHO 
guidelines.6 According to these guidelines trachoma is a public health problem in  three (Gwer 
East, Okpokwu and Ukum) LGAs. Two LGAs (Gwer East and Okpokwu) require public health-
level implementation of the S component of the SAFE strategy and two LGAs (Gwer East and 
Ukum) also had TF prevalences suggesting a need for the A, F and E components of SAFE. 
Similarly community interventions including the A, F and E components of the SAFE strategy 
may be continued in the remaining 21 LGAs with TF levels below 5% and trichiasis levels below 
0.2% in order to sustain the low levels of trachoma estimates recorded in these LGAs. WHO 
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guidelines show that districts with TF estimates ranging from ≥5% to 9.9 % would need at least 
one round of mass antibiotics treatment and those with TF estimates ranging from ≥10 to 20.9% 
would need at least three rounds of mass antibiotics treatment6. Gwer East and Okpokwu LGAs 
will need one round each of mass antibiotics administration. 
Trichiasis levels in two LGAs (Gwer East and Okpokwu) were also found to be more than the 
0.2% threshold stipulated by WHO. This implies that trichiasis surgeries need to be conducted in 
these LGAs. However the observed trichiasis prevalence only translates to an easily manageable 
number of 173 cases needing surgery in these 2 LGAs to reduce the prevalence to less than the 
elimination threshold, ignoring incident disease and mortality. Both of the latter LGAs (Gwer East 
and Ukum) had TF prevalence estimates just above the 5% elimination threshold, with 95%CI 
lower bounds from 3.0–4.0%, and it is eminently possible that these estimates are simply statistical 
outliers, rather than representations of ongoing C. trachomatis transmission that should trigger 
public health concern. However, hard thresholds for elimination must be (and have been) defined, 
and implementation of interventions for neglected tropical disease elimination are justifiable in 
such cases on the basis of apparent very low risk, high community acceptability, and a range of 
benefits to communities beyond simply bringing about the end of the diseases in question.28,29  
Many reports,3,4,16 including a recent global review,17 have shown gender inequality in trachoma 
infection, this study reports a similar trend with females being more susceptible to both TF and 
trichiasis compared to males. The disproportionate association of trichiasis to women compared to 
men has been attributed to women’s role of taking care of the mostly TF susceptible children, 
leading to repeated exposure of women to trachoma infections.19 Females must therefore be of 
prime interest in any future trachoma control programme in this state. The predominance of TF 
among children of lower age-groups (1-9) and trichiasis among adults has also been confirmed in 
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this study just as reported by previous studies. 3, 16, 20, 21, 22 Children within this age group have 
inadequate capacity to take care of themselves and to observe good sanitation practices and are 
most likely to be involved in close contact activity which can promote easy transmission of 
trachoma infection among them. Persons with TF in this study were 1.74 times as likely to be 
below 9 years of age while the odds of trichiasis was 8.9 times among adults over 15 years old. 
The potential risk factors for trachoma identified in this study included age, female gender, 
difficulty in access to drinking water, absence of improved latrine facility and difficulty in access 
to latrine facility. The odds of trachoma was 1.72 times more among households who travel thirty 
minutes or more to get drinking water compared to those who get their drinking water from a closer 
source. Similarly families who do not have latrine facility in their yard or close by had a higher 
odds of having trachoma compared to those who have latrine facilities in their household. These 
findings were in line with investigations conducted by other researchers.21, 22, 25 
The prevalence of TF was highest in Gwer East (5.3%) and Ukum (5.2%). Expectedly in Ukum, 
less than half (45.44%) of the households had access to improved water source, only 6.31% could 
easily access the water source available and only 12.32% had access to latrine facility (improved 
sanitation). The lack of these facilities could have contributed to the high level of TF in these 
LGAs. Access to water and latrine facility were equally low in Gwer East (Table 5). In contrast 
Apa recorded the lowest TF prevalence (0.3%) estimate even though the LGA lacked access to 
improved drinking water sources (0.93%) and latrine facilities (18.99%). The low level of TF in 
this LGA despite these challenges can be attributed to the short distance their residents have to 
travel to get water from the few improved sources available. Nearly all (100%) of households in 
Apa have easy access to water (<1km from household). This finding is worth noting as it buttresses 
the importance of households having “easy” access to water for personal and environmental 
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hygiene practices. This finding does however not in any way diminish the value of providing 
adequate improved sources of water and sanitation facilities for trachoma endemic communities 
as these interventions have been widely reported to enhance effective control of the disease.21,26 
Overall 13 LGAs had coverage of improved water source less than a national average water 
coverage of 56%, coverage of latrine facility in 14 LGAs was less than a national average of 27%.23 
Inaccessibility to latrine facility was associated with a higher odds of trachoma in this study (AOR: 
1.22 95% CI: 1.08 – 1. 37), a finding that is consistent with previous reports.21 Inaccessibility to 
latrine can lead to exposure of household residents to human faeces which are a major breeding 
ground for trachoma vectors Musca sorbens. One would have thought that inaccessibility to 
improved latrine facility may be associated with higher risk for trichiasis. This study however 
found otherwise. This finding is at variance with other studies, however this may be the effect of 
an unmeasured confounding variable or the fact that access to latrine facility alone is inadequate 
in preventing trachoma but rather a concerted effort of education, health promotion and transfer of 
basic techniques of hygienic practices. 24 Clearly trachoma prevalence was low in Benue State 
despite inadequate access to water and sanitation (Table 8). Though recent work30, 31 has begun to 
explore levels of community WASH coverage that might associate with lower risk of active 
trachoma, it does not necessarily follow that particular coverage levels are necessary or sufficient 
for active trachoma to be eliminated. Regardless, water and sanitation are human rights, and 
extension of these services to all residents of Benue should be vigorously pursued 
Excluding new incident cases that may have occurred years after the conduct of this study, about 
173 trichiasis surgeries are needed in order to eliminate trachoma as a public health problem in 
Benue state. The LGA level prevalence estimates provide a guide for programme organizers to 
target communities that are highly endemic and urgently need these services. 
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The study is limited by the arbitrary methods used to estimate some of the outcomes. Outcomes 
like source of drinking and face washing water, distance to water source and distance to latrine 
facility were based on household heads’ response to questionnaires. Additionally, observed 
trachoma cases could not be confirmed by advanced laboratory tests, this can lead to a case of 
over- exaggerated trachoma prevalence by other differential diagnosis which can obscure the true 
magnitude of the problem of trachoma in Benue state. Relatively low numbers of adults were 
examined in several LGAs (771 in Tarka, 997 in Guma; in both of these LGAs no examined adults 
had trichiasis) and the lack of data on the presence or absence of trachomatous conjunctival scar 
in eyes diagnosed as having trichiasis. However, the very low prevalences of trichiasis observed 
almost uniformly across the state would support an assertion that trachoma is close to being 
eliminated in this setting. 
Trachoma is a public health problem in some communities of Benue state, stakeholders must 
immediately start dialogues aimed at collaborative trachoma elimination through the 
implementation of WHO prescribed programmes.  
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APPENDIX A: Informed Consent Forms 
Participant Information Form 
Participant Information Sheet: Global Trachoma Mapping Project 
 
 
You are being invited to take part in a survey. Before you decide whether or not to take part it is important 
for you to understand why the survey is being done and what it will involve. Please take time to consider 
the following information carefully. Talk to others about the survey if you wish.  
 
Ask us if there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part.  
  
1. What is the purpose of the survey?  
 
Trachoma is an important cause of blindness in many countries, including Nigeria.  There is an international 
goal to eliminate trachoma as a cause of blindness by the year 2020.  The strategy that will be used to 
achieve this goal includes mass treatment with antibiotics, facial cleanliness and environmental changes.  
In order to decide where these interventions need to be conducted, we need to know in detail where 
trachoma is a problem, and in places where it is a problem, what proportion of the community suffers from 
the disease.  We gain that knowledge by conducting surveys, in which we select a number of communities 
from each [district], and from the selected communities select a number of households in which to examine 
residents for the disease. 
  
2. Why have I been chosen?  
 
We are asking 25 communities from your Local Government Area (LGA) to participate in this survey.  
These communities have been chosen by chance selection.  From each of those communities, we are asking 
residents of 25 households to participate. These households have been chosen by chance selection, so that 
each household in this community had an equal chance of being chosen.  Your household is one of the 
chosen households in this community, and we would greatly appreciate it if you would consider taking part. 
  
3. Do I have to take part?  
 
No. It is up to you to decide whether or not to take part. If you do, you will be asked to give consent to 
participate. You are still free to withdraw at any time and without giving a reason. A decision to withdraw 
at any time, or a decision not to take part, will not affect the standard of medical or ophthalmic care you 
receive.  A copy of this information sheet will be given to the head of the community. 
  
4. What will happen to me if I take part?  
 
If you agree to take part, we will ask you some questions about water and sanitation for your household, 
ask to look at your latrine (if you have one), record information about the age and gender of the residents 
of the household, and examine everyone’s eyes for signs of trachoma.  Examination involves looking at the 
eye using a torch and magnifying glasses, including looking underneath the upper eyelid.  All of these 
things are standard procedures: nothing experimental is being undertaken. 
 
No blood or other samples will be taken.   
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No follow-up visits are planned, but the information that we collect may indicate that trachoma elimination 
activities are needed in this [district].  If this is the case, the Ministry of Health will make appropriate 
arrangements to begin interventions. 
 
 
5. Are there any possible risks or benefits to me of taking part?  
 
Having your eyes examined for trachoma is minimally uncomfortable but not painful, and will not affect 
your vision.  The whole process, including asking questions and examination of all household residents, 
should take less than 15 minutes. 
 
If we find trachoma or other medical problems, we will offer treatment or referral to a health clinic. 
 
If we find that trachoma is a public health problem in the [district], the Ministry of Health will be able to 
launch a programme to eliminate the disease. 
 
6. Will my taking part in the survey be kept confidential?  
 
If you participate, some of the data collected for the study will be looked at by authorised persons from the 
Ministry of Health, the London School of Hygiene & Tropical Medicine, Sightsavers UK, and the 
International Trachoma Initiative. They may also be looked at by representatives of regulatory authorities 
to check that the survey is being carried out correctly.  All will have a duty of confidentiality to you as a 
survey participant and nothing that could reveal your identity will be disclosed outside the project group.  
 
7. What will happen to the results of the survey?  
 
Results of the survey will be used by the Ministry of Health to determine whether or not a trachoma 
elimination programme is needed here.  [District]- and national-level results will be published in the 
medical literature. You and your family will not be personally identified in any report or publication. 
.  
8. Who is organising and funding the survey?  
 
The surveys are organised by [local partner] in collaboration with the London School of Hygiene & Tropical 
Medicine and Sightsavers UK.  Money for the surveys has been provided by the UK’s Department for 
International Development. 
 
9. Who has reviewed the protocol for this survey?  
 
This survey was given a favourable ethical opinion by the National Research Ethics Committee.  
 
 
 
Thank you for taking the time to read this sheet. 
 
Caleb Mpyet 
Sightsavers  
No 1 Golf Course Road 
Kaduna, Nigeria 
08033887970 
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Consent Forms 
 
Consent form 
Global Trachoma Mapping Project  
Nigeria. 
Name of participant: ...............................................................................................  
Date: ................................................................... 
Please tick the correct boxes 
I have read the information sheet and understand what I am being asked to do  Yes 
   
  No 
   
My questions have been answered  Yes 
   
  No 
   
I agree to be examined  Yes 
   
  No 
   
I agree to anonymous results being used in reports or publications  Yes 
   
  No 
   
I agree to take part in this project  Yes 
   
  No 
 
Sign/thumbprint_______________________________________________________________ 
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APPENDIX B: Data collection tools 
[GTMP] Trachoma baseline prevalence survey Date  
 
(A) Household questionnaire       Recorder 
 
Section 1: Identifying information  
1 Country [write name or put code in boxes]  
2 Evaluation Unit [write name or put code in boxes]  
3 Cluster [write name or put code in boxes]  
4 Household [write name of household head or put code in boxes]  
Section 2: Household information and GPS 
G1 Latitude (N)                       .  
G2 Longitude (E)                       . 
G3 Elevation (metres)  
G4 Accuracy (metres)  
Section 3: Water, sanitation and hygiene questions  
W1 
 
 
 
In the dry season, what is the main source of drinking 
water for members of your household?  
1. 01=Piped water into dwelling 
2. 02=Piped water to yard/plot 
3. 03=Public tap/standpipe 
4. 04=Tubewell/borehole 
5. 05=Protected dug well 
6. 06=Unprotected dug well 
7. 07=Protected spring 
8. 08=Unprotected spring 
9. 09=Rainwater collection 
10. 10=Water vendor 
11. 11=Surface water (e.g. river, dam, lake, canal) 
12. 99=Other (specify) 
W2 
 
 
How long does it take to go there, get water, and come 
back? 
1. 1=Water source in the yard 
2. 2=Less than 30 minutes 
3. 3=Between 30minutes and 1 hour 
4. 4=More than 1 hour 
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W3 In the dry season, what is the main source of water 
used by your household for washing faces? 
13. 01=Piped water into dwelling 
14. 02=Piped water to yard/plot 
15. 03=Public tap/standpipe 
16. 04=Tubewell/borehole 
17. 05=Protected dug well 
18. 06=Unprotected dug well 
19. 07=Protected spring 
20. 08=Unprotected spring 
21. 09=Rainwater collection 
22. 10=Water vendor 
23. 11=Surface water (e.g. river, dam, lake, canal) 
99=Other (specify) 
W4 If you collected water there to bring back to the house, 
how long would it take to go there, get water, and 
come back? 
 
5. 0=All face washing done at water source 
6. 1=Water source in the yard 
7. 2=Less than 30 minutes 
8. 3=Between 30minutes and 1 hour 
4=More than 1 hour 
S1 Where do you and other adults in the household 
usually defaecate? 
1=Shared or public latrine 
2=Private latrine 
3=No structure, outside near the house 
4=No structure, in the bush or field 
9=Other 
S2 Ask to see the latrine/toilet. 
Observation: 
What kind of toilet facility do the adults in the 
household use? 
 
 
a. 01=Flush/pour flush to piped sewer system 
b. 02=Flush/pour flush to septic tank 
c. 03=Flush/pour flush to pit latrine 
d. 04=Flush/pour flush to open drains 
e. 05=Flush/pour flush to unknown place 
2. 06=Ventilated improved pit latrine (VIP) 
3. 07=Pit latrine with slab 
4. 08=Pit latrine without slab/open pit 
5. 09=Composting toilet 
6. 10=Bucket 
7. 11=Hanging toilet/hanging latrine 
8. 12=No facilities or bush or field 
9. 99=Other (specify) 
   
H1 
Observation: Is there a handwashing facility within 15 
meters of the latrine/toilet? 
. 0=No 
1=Yes 
5=Not applicable (no latrine/toilet) 
H2 Observation: At the time of the visit, is water 
available at the handwashing facility? 
0=No 
1=Yes 
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5=Not applicable (no handwashing facility) 
H3 Observation: At the time of the visit, is soap or ash 
available at the handwashing facility? 
0=No 
1=Yes 
5=Not applicable (no handwashing facility) 
 
(B) Census and examination findings 
 
Country      EU        Cluster                 Household       
Recorder    
List all household residents. Ask for consent to examine all 1-9 year-olds and all  those aged ≥15 
years.  Mop-up should focus on 1-9 year-olds. 
ID 
number 
Name 
Sex 
[1=M; 
2=F] 
Age 
(years) 
Examined? 
[1=Yes 
(with 
consent); 
2=Absent; 
3=Refused; 
4=Other] 
Right Eye 
0=Sign absent; 
1=Sign present 
Left Eye 
0=Sign absent; 
1=Sign present 
Notes 
TT TF TI TT TF TI 
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APPENDIX C: Letter of approval from research ethics committees 
Approval from NHREC of Nigeria 
 
 
NHREC Protocol Number NHREC/01/01/2007-16/04/2013 
NHREC Approval Number NHREC/01/01/2007-19/05/2013 
Date: 21st May, 2013 
RE: GLOBAL TRACHOMA MAPPING PROJECT-NIGERIA 
Health Research Ethics Committee (HREC) assigned number: NHREC/01/01/2007 
Name of Principal Investigator: Prof. Caleb Mpyet 
Address of Investigator: Jos University Teaching Hospital 
Plateau State, Nigeria 
Date of receipt of valid application: 16-04-2013 
Date when final determination of research was made: 19-05-2013 
Notice of Full Committee Review and Approval 
This is to inform you that the research described in the submitted protocol, the consent forms, other participant information materials 
have been reviewed and granted full committee approval by the National Health Research Ethics Committee. 
This approval dates remain as in the initial approval from 19/05/2013 to 18/05/2014. If there is delay in starting the research, please 
inform the HREC so that the dates of approval can be adjusted accordingly. Note that no participant accrual or activity related to 
this research may be conducted outside of these dates. All informed consent forms used inthis study must carry the HREC assigned 
number and duration of HREC approval of the study. If this is a multi-year research, endeavor to submit your annual report 
to the HREC early in order to obtain renewal of your approval and avoid disruption of your research. 
The National Code for Health Research Ethics requires you to comply with all institutional guidelines, rules and regulations and 
with the tenets of the Code including ensuring that all adverse events are reported promptly to the HREC. 
No changes are permitted in the research without prior approval by the HREC except in circumstances outlined in the Code. The 
HREC reserves the right to conduct compliance visit your research site without previous notification. 
Signed 
Clement Adebamowo BMChB Hons (Jos), FWACS, FACS, DSc (Harvard) 
Honorary Consultant Surgeon, Director, West African Center for Bioethics and 
Chairman, National Health Research Ethics Committee of Nigeria (NHREC) 
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UCT ethics approval letter 
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APPENDIX D: Instructions for authors  
Instructions for authors  
Thank you for choosing to submit your paper to us. These instructions will ensure we have 
everything required so your paper can move through peer review, production and publication 
smoothly. Please take the time to read them and follow the instructions as closely as possible. 
Should you have any queries, please visit our Author Services website or contact us 
at authorqueries@tandf.co.uk.  
This journal uses Scholar One Manuscripts (previously Manuscript Central) to peer review 
manuscript submissions. Please read the guide for ScholarOne authors before making a 
submission. Complete guidelines for preparing and submitting your manuscript to this journal are 
provided below.  
Publishing Ethics 
The Editors and Taylor & Francis Group are committed to the highest academic, professional, 
legal, and ethical standards in publishing work in this journal. To this end, we have adopted a set 
of guidelines, to which all submitting authors are expected to adhere, to assure integrity and ethical 
publishing for authors, reviewers, and editors. 
Taylor & Francis is a member of the Committee of Publications Ethics (COPE). COPE aims to 
provide a forum for publishers and editors of scientific journals to discuss issues relating to the 
integrity of their work, including conflicts of interest, falsification and fabrication of data, 
plagiarism, unethical experimentation, inadequate subject consent, and authorship disputes. For 
more information on COPE please visit http://publicationethics.org. 
Instructions for Authors  
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All submissions should be submitted at http://mc.manuscriptcentral.com/nope  
All submissions should be double spaced, with consecutively numbered pages.  
All abbreviations/acronyms must be defined at first use in the abstract, again at first use in the text 
and in each and every table or figure, regardless of seeming redundancy.  
The following are the files need to make your online submission complete: 
I. MANUSCRIPT FILE  
1.  Cover page –  
    a)  list the title of your submission – no abbreviations or acronyms (acronyms may be 
considered if important for recognition of a prominent study, and in that case they should be used 
only after defining the acronym in the title)  
    b)  supply a running head -  a shortened version of title, not to exceed 50 characters.  If the full 
title is 50 characters or less, they can be the same.  
    c)  list all authors in publication order and their related affiliations,  
    d)  indicate who is the corresponding author and the corresponding contact information 
(especially email),  
    e)  financial support – list all financial support  
    f) list any proprietary interests or conflicts of interest for any and all authors related to this 
submission.  “If none, please state:  None of the following authors have any proprietary interests 
or conflicts of interest related to this submission:”; then list all the authors with no such 
interests.  “None of the authors” suffices if no one has any such interests.  Please err on the side 
of disclosure if it is unclear whether something is an interest or not, and please include 
relationships that may be perceived by others as a conflict of interest.  
    g) statement that this submission has not been published anywhere previously and that it is not 
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simultaneously being considered for any other publication.   Note:  if the paper previously has 
been reviewed and rejected by another journal, please indicate so, and please indicate what 
criticisms were given and what changes have been made in response (as if you were revising and 
resubmitting to the original journal).  We are open to accepting such papers if they have merit, 
and there is no need to hide this information.  
 2.  Abstract – start on new page – not to exceed 250 words, define all abbreviations or 
acronyms used at first use, formatted into the following four sections:      
    a) Purpose  
    b) Methods  
    c) Results  
    d) Conclusion 
3.  Manuscript text – start on a new page.  The text should not exceed 4,000 words.  Define all 
abbreviations and acronyms at first use (even if previously defined in abstract).  The text should 
be divided into the following 5 sections:  
    a) Introduction—give the rationale for why this manuscript is important  
    b) Materials and Methods – should include a statement regarding adherence to the guidelines 
of the Declaration of Helsinki as well as giving the name of the Institutional Review Board 
which granted approval or which indicated approval was not needed.  Any waivers granted, such 
as HIPAA waivers or waiver of consent, should be mentioned.  Whether patients consented to 
participate in the study should be mentioned; if not, the reason why not should be mentioned 
(e.g., Institutional Review Board waiver of consent)  
    c) Results—summarize the key and supportive results in a clear, crisp, straightforward 
manner.  
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    d) Discussion—discuss what the key findings are, how it fits in with existing knowledge on 
the subject, and if there alternative explanations of the observations such as bias or random 
error.  Please include a strengths and limitations paragraph, as well as a concluding paragraph 
summarizing the main items of knowledge that the paper has provided and relevant applications.  
    e) References – Please follow the directions in Section 4 below. 
4. References - cite in the text as superscript by reference number, consecutively as they appear 
in the text, starting with  
I.   Prepare a numbered reference list. Only published and accepted (in press) articles can be 
cited.  Abstracts should be cited parenthetically within the text as should any personal 
communication or unpublished data.  Submitted articles are not citable, and should be referenced 
as unpublished data. Examples: 
Journal:  
Mohney BG, Robertson DM, Schomberg PJ. Second nonocular tumors in survivors of heritable 
retinoblastoma and prior radiation therapy. Am J Ophthalmol. 1998; 126(2):269-277. 
Book:  
Raven JC, Court JH, Raven J. Manual for Raven' Progressive Matrices and Vocabulary Scales. 
London: H.K. Lewis & Co. Ltd., 1986.  
II.   Tables and Figures: Tables and figures should not be embedded in the text, but should be 
included as separate sheets or files. Each figure and table should be a separate file uploaded into 
the system.  A short descriptive title should appear above each table with a clear legend and any 
footnotes suitably identified below. All units must be included. Figures should be completely 
labeled, taking into account necessary size reduction. 
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Figure captions should be typed, double-spaced, in a separate file. All non-electronic original 
figures should be clearly marked with the number, author’s name, and top edge indicated.  If you 
are contemplating submitting non-electronic material, please contact the editorial office to 
discuss whether this can be permitted, and to arrange how to do so.  Non-electronic material 
should be used only if it is impossible to submit electronically, and if the material adds value to 
the manuscript. 
III.   Illustrations: Illustrations submitted (line drawings, halftones, photos, photomicrographs, 
etc.) should be clean originals or digital files. Digital files are recommended for highest quality 
reproduction and should follow these guidelines:  
• 300 dpi or higher  
• sized to fit on journal page  
• EPS, TIFF, or PSD format only  
• submitted as separate files, not embedded in text files 
Color Reproduction: Color art will be reproduced in color in the online publication at no 
additional cost to the author. Color illustrations also will be considered for print publication; 
however, the author will be required to bear the full cost involved in color art reproduction for 
the print publication.  
Please note that color reprints only can be ordered if print reproduction costs are paid. Print 
Rates: $900 for the first page of color; $450 per page for the next three pages of color. A custom 
quote will be provided for articles with more than four pages of color. 
Art not supplied at a minimum of 300 dpi will not be considered for print. 
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IV.   Copyright Form(s) – available upon article acceptance  
It is a condition of publication that authors assign copyright or license the publication rights of 
the contents of their articles, including abstracts, to Taylor and Francis. This enables full 
copyright protection and dissemination of the article and the Journal, to the widest possible 
readership in electronic and print formats. A document to verify this will be sent upon 
acceptance for publication. This document should be signed by the corresponding author and 
returned to the publisher for archiving. 
V.   Acknowledgements:  The journal will print acknowledgements if requested by authors, 
please do not confuse this with financial support.  It is requested that these are kept to a 
minimum.   If you wish to acknowledge those who reviewed, discussed, translated references, 
provided extensive statistical assistance, or provided essential research material, equipment, or 
other materials without which the study could not have been completed, written permission from 
the person being acknowledged is required. The corresponding author should indicate that such 
permission has been obtained in advance of submission in a cover letter. 
OTHER GENERAL INFORMATION:  
Expedited review generally can be organized for exceptionally high impact manuscripts by 
special arrangement with the Editor-in-Chief or his/her designee.  Please contact the Editor-in-
Chief directly at ophthalmic.epidemiology@gmail.com to request expedited review; please 
include a brief summary of the nature of the article, and your rationale as to why expedited 
review is justified. 
 
Systematic review and meta-analysis projects should follow a research protocol that is developed 
and published or registered with Prospero, prior to the conduct of the review.    
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Reports of systematic review and meta-analysis should be prepared according to the PRISMA 
Statement (website http://www.prisma-statement.org/).        
Reports of observational studies are strongly recommended to be prepared according to 
the STROBE Statement (website http://www.strobe-statement.org/index.php?id=strobe-home). 
Reports of clinical trial primary results are strongly recommended to be prepared in accordance 
with CONSORT Guidelines. 
Permissions: Authors are responsible for obtaining permission to reproduce copyrighted 
material from other sources and are required to sign an agreement for the transfer of copyright to 
the publisher. As an author you are required to secure permission if you want to reproduce any 
figure, table or extract text from any other source. This applies to direct reproduction as well as 
"derivative reproduction" (where you have created a new figure or table which derives 
substantially from a copyrighted source).   It is the responsibility of the author to pay any fees 
associated with such permissions. 
Page Proofs: All proofs must be corrected and returned to the publisher within 48 hours of 
receipt. Only correction of typographical errors is permitted. 
Complimentary Access and Reprints: Authors for whom we receive a valid email address will 
be provided an opportunity to purchase reprints of individual articles, or copies of the complete 
print issue. These authors will also be given complimentary access to their final article on Taylor 
& Francis Online. 
SUBMISSION PROCESS: 
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1.   LOG IN AT:   http://mc.manuscriptcentral.com/nope  
2.   REGISTER AS AUTHOR – be sure you are not already in the system  
3.   SELECT TYPE OF MANUSCRIPT  
4.   SUPPLY TITLE OF MANUSCRIPT  
5.  ABSTRACT:  Copy and paste your abstract from your manuscript file  
6.  KEYWORDS:  Supply minimum of 5 key words for your submission  
7.  AUTHORS:  enter the names and information of all authors.  Please verify the exact spelling 
carefully.  
8.  REVIEWERS:  You can indicate the names of persons you prefer to or not to review your 
submission.  Such suggestions are considered but choice of reviewers ultimately is at the 
discretion of the Editorial Board members involved in review of the article.  
9.  DETAILS AND COMMENTS:  You must answer certain mandatory questions  
        Total number of figures in your submission (black and white as well as color)  
        Number of color figures  
        Number of tables  
        Number of words  
Consent to pay for color figures (when applicable)  
Confirm that the manuscript has been submitted for consideration of publication solely to this 
journal and is not published, in press, or submitted for potential publication elsewhere.  
Confirm that all the research meets the ethical guidelines, including adherence to the legal 
requirements of the study country and that a statement is included in the manuscript regarding 
IRB approval (see instructions above).  
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Confirm any potential conflict of interests (see instructions above).  
Confirm you are aware of copyright issues  
10. UPLOAD FILES:  manuscript:  including cover page, abstract text and references, tables and 
each figure  
11.    REVIEW that these are the correct files in the correct order, etc.  
12.   SUBMIT 
Open Access  
Articles are eligible for Open Access. Electing this option allows the article to be made freely 
available online under a Creative Commons License. Authors of accepted papers will have the 
opportunity to purchase open access at proofs stage. Please note: This option is separate from 
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APPENDIX E: Supplementary tables 
Table 5: Socio demographic and household characteristics of participants Global Trachoma 
Mapping Project, Benue state, Nigeria, April –September 2014. 
Factors Frequency Percentage 
Age of Participants   
1-9 44,056 47.05% 
≥15 38,045 40.63% 
   
Gender   
Males 46,194 49.33% 
Females 47,442 50.67% 
   
Household Source of water for 
drinking and face washing 
  
Piped water into dwelling 11 0.01% 
Piped water into yard/plot 10 0.01% 
Public tap/standpipe 310 0.33% 
Tube well/borehole 14,225 15.19% 
Protected dug well 21,236 22.68% 
Unprotected dug well 9,912 10.59% 
Protected spring 2,440 2.61% 
Unprotected spring 9,586 10.59% 
Rain water collection 268 0.29% 
Water vendor 1,929 2.61% 
Surface water(river, dam, lake, 
canal) 
33,639 35.93% 
Others(stream, borehole and 
protected well, water vendor 
&borehole) 
70 0.07% 
   
Distance to drinking water source   
Water source in the yard 19,563 20.89% 
Less than 30 minutes from HH 31,362 33.49% 
Between 30 minutes and 1 hour 
from HH 
25,149 26.86% 
More than an hour from HH 17,562 18.76% 
   
Distance to face washing water 
source 
  
Face washing done at water source 3,777 4.03% 
Water source in yard of HH 19,508 20.83% 
Less than 30 minutes from HH 28,565 30.51% 
Between 30 minutes and  1 hour 
from HH 
24,413 26.07% 
More than an hour from HH 17,373 18.55% 
   
Household latrine facility   
Shared latrine 23,104 24.67% 
Private latrine 17,103 18.27% 
No structure, outside near the 
household 
4,734 5.06% 
No structure, in the bush or field 47,905 51.16% 
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Others  790 0.84% 
   
Types  of latrines   
Flush/pour flash to piped sewer 
system 
36 0.04% 
Flush/pour flush to septic tank 4,797 5.12% 
Flush/pour flush to pit latrine 2,813 3.00% 
Flush/pour flush to open drains 14 0.01% 
Flush/pour flush to unknown place  8 0.01% 
Ventilated improved pit latrine 
VIP 
1,062 1.13% 
Pit latrine with slab 17,704 18.91% 
Pit latrine without slab/open pit 14,542 15.53% 
Composting toilet 16 0.02% 
Hanging toilet/hanging latrine 34 0.04% 
No facility/bush/field 52,483 56.05% 
Others (buried/bush) 127 0.14% 
   
Hand washing facility within 15 
minutes of  latrine/toilet 
  
Present  5,268  5.63% 
Absent 1,192 1.27% 
No latrine/toilet/not applicable 87,176 93.10% 
   
Soap/ash for hand washing at 
facility 
  
Present 3,946 2.68% 
Absent 2,507 4.21% 
No latrine/toilet/not application 87,183 93.11% 
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Table 6: LGA level prevalence of TF and trachoma burden, Global Trachoma Mapping Project, 
Benue state, Nigeria, April – September 2014. 
LGA Total 
Population 
estimate 
for persons 
0-9 years 
old  
Number of 
persons 1-
9 years old 
examined 
Number 
of TF 
cases 
observed 
TF Prevalence (%)(95% 
CI)b 
Ado 65,725 3,449 120 3.0 (2.1–4.2) 
Agatu 41,946 4,053 23 0.5 (0.3–0.7) 
Apa 34,715 2,109 8 0.3 (0.1–0.5) 
Buruku 72,919 1,309 17 1.8 (0.7–3.4) 
Gboko 112,383 1,235 5 0.3 (0.1–0.7) 
Guma 70,591 1,708 80 4.2 (3.2–5.4) 
Gwer East 58,523 1,433 91 5.3 (3.3–7.7) 
Gwer West 44,410 1,373 62 4.6 (2.9–6.6) 
Katsina-Ala 77,848 1,172 28 1.9 (1.0–2.7) 
Konshisha 78,592 1,972 17 0.8 (0.4–1.4) 
Kwande 85,065 1,442 11 0.6 (0.3–0.9) 
Logo 59,679 2,059 17 0.7 (0.3–0.9) 
Makurdi 86,326 1,378 27 1.8 (0.7–2.8) 
Obi 35,418 3,821 95 2.3 (1.5–3.2) 
Ogbadibo 44,726 1042 41 3.5 (1.8–5.1) 
Ohimini 24,698 3,072 23 0.8 (0.5–1.2) 
Oju 56,060 1,189 21 1.5 (0.8–2.3) 
Okpokwu 60,410 1,012 8 0.5 (0.1–0.8) 
Oturkpo 84,744 1,462 9 0.7 (0.2–1.5) 
Tarka 28,879 3,145 34 1.6 (0.8–2.7) 
Ukum 76,373 1,111 66 5.2 (3.6–7.0) 
Ushongo 66,589 1,701 24 1.1 (0.4–2.3) 
Vandeikya 78,954 1,393 48 2.8 (1.5–4.7) 
Total 1,445,573 43,640 875  
bAdjusted for age, in 1-year bands 
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Table 7: Local Government Area (LGA-level) estimates of trichiasis backlog, Global Trachoma 
Mapping Project, Benue state, Nigeria, April-September 2014. 
LGA Total 
Population 
estimate for 
persons ≥15 
years 
Number 
of persons 
≥15 
examined 
Number 
of 
trichiasis 
observed 
Trichiasis 
Prevalence 
(%)(95%CI)a 
Estimated  
trichiasis 
backlog 
Number of 
trichiasis 
surgeries 
needed to be 
conducted to 
eliminate 
trachoma 
Ado 97,142 2,087 11 0.19 (0.07–0.34) 187 0 
Agatu 60,493 1,572 0 0 0 0 
Apa 51,001 1,426 0 0 0 0 
Buruku 108,425 1,364 0 0 0 0 
Gboko 202,010 1,750 0 0 0 0 
Guma 101,355 997 1 0.01 (0.00–0.02) 6 0 
Gwer East 90,299 1,709 5    0.23 (0.00– 
0.52) 
210 29 
Gwer West 63,901 1,175 0 0 0 0 
Katsina-Ala 120,884 1,600 10 0.19 (0.03–0.43) 228 0 
Konshisha 120,147 1,302 0 0 0 0 
Kwande 133,246 1,265 0 0 0 0 
Logo 89,816 2,938 0 0 0 0 
Makurdi 176,405 1,879 0 0 0 0 
Obi 52,081 1,883 0 0 0 0 
Ogbadibo 70,791 1,657 1 0.01 (0.00–0.02) 5 0 
Ohimini 37,847 2,644 1 0.03 (0.00–0.09) 11 0 
Oju 92,435 1,481 0 0 0 0 
Okpokwu 94,565 1,152 12 0.35 (0.12–0.50) 333 144 
Oturkpo 148,700 1,322 0 0 0 0 
Tarka 41,295 771 0 0 0 0 
Ukum 115,173 1,341 0 0 0 0 
Ushongo 101,497 1,545 1 0.08 (0.00–0.25) 84 0 
Vandeikya 125,214 1,942 0 0 0 0 
Total 2,294,722 36,802 42  1,064 173 
aAdjusted for gender and age, in 5-year bands 
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Table 8: Household (HH) access to improved water and latrine facility by LGA, Global Trachoma 
Mapping Project, Benue state, Nigeria, April-September 2014. 
LGA HH With access to 
improved drinking 
water source (%) 
HH with easy access 
to drinking  water 
source  
HH with access to 
improved sanitation 
(latrine access) 
Ado  20.49 46.79 31.38 
Agatu    9.09 37.39 14.59 
Apa     0.93 100.00 18.99 
Buruku  69.57 80.37 17.25 
Gboko    35.96 55.06 37.58 
Guma    25.78 46.39 20.09 
Gwer East    67.66  49.99 11.63 
Gwer West   0.07 8.06 1.38 
Katsina-Ala    62.56 74.85 51.21 
Konshisha     57.32 67.57 5.22 
Kwande    72.39 81.08 26.17 
Logo       33.88 31.41 50.10 
Makurdi  64.49 37.93 49.78 
Obi      28.36 14.78 3.36 
Ogbadibo      43.14 96.00 33.87 
Ohimini      13.94 57.31 25.25 
Oju       61.24 12.07 2.29 
Okpokwu  3.13 59.20 80.43 
Oturkpo     50.60 98.80 92.16 
Tarka      98.79 70.87 45.53 
Ukum  45.44 6.31 12.32 
Ushongo  69.98 65.99 17.31 
Vandeikya    57.26  98.94 16.09 
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Table 9: Univariate and multivariate logistic regression analysis of factors associated with 
Trachomatous Follicular (TF) among children 1-9 years Global Trachoma Mapping Project, Benue 
state, Nigeria, April–September 2014. 
Variable TF Presence Univariate model P-value Multivariate 
model 
P-value 
Age YES (%) NO (%) COR(95%CI)  AOR(95%CI)  
1-9 710(1.63) 42928(98.63) 1.77(1.55 – 2.02) <0.001 1.74(1.53 – 1.99) <0.001 
≥15 340(0.92) 36457(99.08) 1  1  
       
Sex       
Females 596(1.44) 40,827(98.56) 1.21(1.06 – 1.36) 0.013 1.28(1.14 – 1.45) <0.001 
Males 454(1.16) 38,558(98.84) 1  1  
       
Source of drinking water     
Unsafe 669(1.40) 47,199(98.60) 1.20(1.06 – 1.46) 0.006 0.77(0.40 – 1.46) 0.421 
Safe 380(1.17) 32,134(98.83) 1  1  
       
Time to haul drinking water      
≥30 min. walk 481(1.10) 43,313(98.90) 1.42(1.26 – 1.60) <0.001 1.72(1.09 – 2.70) 0.019 
≤30 min. walk 568(1.55) 36,020(98.45) 1  1  
       
Source of face washing water     
Unimproved 674(1,40) 47,372(98.60) 1.21(1.07 – 1.38) 0.003 1.36((0.71 – 2.59) 0.351 
Improved 375(1.16) 31,961(98.84) 1  1  
       
Time to haul face-washing water     
≥30 min. walk 499(1.12) 44,049(98.88) 1.38(1.22 – 1.55) <0.001 0.72(0.46 – 1.14) 0.160 
≤30 min. walk 550(1.53) 35,284(98.47) 1  1  
       
Latrine facility       
Absent 710((1.52) 45,891(98.48) 1.53(1.34 – 1.74) <0.001 0.62(0.38 – 1.00 0.052 
Present 339(1.00) 33,442(99.00) 1  1  
       
Latrine facility       
Unimproved 878(1.51) 57,367(98.49) 1.00(0.97 – 1.02) 0.770 1.00(0.96 – 1.03) 0.708 
Improved 171(0.78) 21,847(99.22) 1  1  
       
Easy Accessibility of latrine facility    
NO 302(1.04) 28,629(98.96) 1.13(1.09 – 1.16) <0.001 1.22(1.08 – 1. 37) 0.002 
YES 32(0.59) 5,421(99.41) 1  1  
       
Water at facility       
Absent 4(0.41) 982(99.59) 1.19(1.10 – 1.28) <0.001 0.74(0.44 – 1.25) 0.261 
Present 28(0.63) 4,439(99.37) 1  1  
       
Soap at facility       
Absent 14(0.67) 2,072(99.33) 1.20(1.11 – 1.30) <0.001 1.46(0.84 – 2.53) 0.176 
Present 18(0.54) 3,343(99.46) 1  1  
COR: Crude Odds Ratio; AOR: Adjusted Odds Ratio; CI: Confidence Interval. Environmental risk factors were 
categorized (Improved, unimproved, water source ≥/≤30 min. walk) according to the WHO/UNICEF Joint 
Monitoring Program (JMP) for Water Supply and Sanitation’s “Sanitation Ladder” from the 2008 JMP Report 
(http://www.wssinfo.org/fileadmin/user_upload/resources/1251794333-JMP_08_en.pdf). All risk factors for both TF 
and trichiasis were recoded to binary variables to make for easy analysis and interpretation. 
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Table 10: Univariate and multivariate logistic regression analysis of factors associated with 
trichiasis among adults ≥ 15 years old Global Trachoma Mapping Project, Benue state, Nigeria, 
April –September 2014. 
Variable Trichiasis Presence Univariate model P-
value 
Multivariate model P-value 
Age YES (%) NO (%) COR(95%CI)  AOR  
≥15 26(0.07) 36,771(99.93) 10.28(3.11 -   33.98) <0.001 8.94(2.70 – 29.64) <0.001 
1-9 3(0.01) 43,635 1  1  
       
Sex       
Females 19(0.05) 41,404(99.95) 1.79(0.83 – 3.85) 0.136 1.60(0.74 – 3.44) 0.232 
Males 10(0.03) 39,002(99.97) 1  1  
       
Source of drinking water     
Unsafe 22(0.05) 47,846(99.95) 1.00(0.92 – 1.11) 0.842 1.01(0.93 – 1.10) 0.840 
Safe 7(0.02) 32,507(99.98) 1  1  
       
Time to haul drinking water  
  
    
≤30 min. walk 13(0.03) 43,834(99.97) 1.47(0.71 – 3.07) 0.298 2.12(0.98 – 4.58) 0.057 
≥30 min. walk 16(0.04) 36,572(99.96) 1  1  
       
Source of face washing water     
Unimproved 22(0.05) 48,024(99.95) 1.01(0.92 – 1.11) 0.842 - - 
Improved 7(0.02) 32,329(99.98) 1    
       
Time to haul face-washing water     
≤30 min. walk 13(0.03) 44,588(99.97) 1.53(0.74 – 3.19) 0.253 - - 
≥30 min. walk 16(0.04) 35,818(99.96) 1    
       
Latrine Facility      
Absent 10(0.02) 46,598(99.98) 0.38(0.18 – 0.82) 0.014 4.39(1.00 – 19.18) 0.049 
Present 19(0.06) 33,808(99.94) 1  1  
       
Latrine facility     
Unimproved 10(0.02) 58,242(99.98) 0.20(0.09 – 0.43) <0.001 0.15(0.04 – 0.67) 0.012 
Improved 19(0.09) 22,045(99.91) 1  1  
       
Easy Accessibility of latrine facility     
NO 19(0.07) 28,938(99.93) 0.76(0.63 – 0.91) 0.003 0.73(0.44 – 1.22) 0.231 
YES 2(0.04) 5,471(99.96) 1  1  
       
Water at facility     
Absent 0 1,006(100.000 1.00(0.74 – 1.32) 0.940 0.71(0.13 – 3.85) 0.693 
Present 2(0.04) 4,465(99.96) 1  1  
       
Soap at facility     
Absent 1(0.05) 2,105(99.95) 1.00(0.73 – 1.37) 0.988 1.83(0.29 – 11.58) 0.522 
Present 1(0.03) 3,360(99.97) 1  1  
NB: COR: Crude Odds Ratio; AOR: Adjusted Odds Ratio; CI: Confidence Interval. Environmental risk factors were 
categorized (Improved, unimproved, water source ≥/≤30 min. walk) according to the WHO/UNICEF Joint Monitoring 
Program (JMP) for Water Supply and Sanitation’s “Sanitation Ladder” from the 2008 JMP Report 
(http://www.wssinfo.org/fileadmin/user_upload/resources/1251794333-JMP_08_en.pdf). All risk factors for both TF 
and trichiasis were recoded to binary variables to make for easy analysis and interpretation. “Source of face washing 
water” and “Time to haul  face washing water” were excluded from the multivariate analysis because of perceived 
collinearity with “Source of drinking water” and “Time to haul drinking water” respectively. 
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APPENDIX F: Figures 
 
 
 
 
 
